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1. Preamble
Guidelines summarize and evaluate available evidence with the aim of
assisting health professionals in selecting the best management strat-
egies for an individual patient with a given condition. Guidelines and
their recommendations should facilitate decision making of health pro-
fessionals in their daily practice. However, the final decisions concerning
an individual patient must be made by the responsible health professio-
nal(s) in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent
years by the European Society of Cardiology (ESC) and by the
European Association for Cardio-Thoracic Surgery (EACTS) as
well as by other societies and organisations. Because of the impact
on clinical practice, quality criteria for the development
of guidelines have been established in order to make all
decisions transparent to the user. The recommendations for
formulating and issuing ESC Guidelines can be found on the ESC
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..website (https://www.escardio.org/Guidelines/Clinical-Practice-Guide
lines/Guidelines-development/Writing-ESC-Guidelines). ESC Guide-
lines represent the official position of the ESC on a given topic and
are regularly updated.
Members of this Task Force were selected by the ESC and EACTS
to represent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a com-
prehensive review of the published evidence for management of a
given condition according to ESC Committee for Practice Guidelines
(CPG) policy and approved by the EACTS. A critical evaluation of
diagnostic and therapeutic procedures was performed, including
assessment of the risk–benefit ratio. The level of evidence and the
strength of the recommendation of particular management options
were weighed and graded according to predefined scales, as outlined
in Tables 1 and 2.
The experts of the writing and reviewing panels provided declara-
tion of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of interest
that arise during the writing period were notified to the ESC and
EACTS and updated. The Task Force received its entire financial sup-
port from the ESC and EACTS without any involvement from the
healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines. The Committee is also responsible for the endorsement
process of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts, and in this case by EACTS-
appointed experts. After appropriate revisions the Guidelines are
approved by all the experts involved in the Task Force. The finalized
document is approved by the CPG and EACTS for publication in
the European Heart Journal and in the European Journal of
Cardio-Thoracic Surgery. The Guidelines were developed after care-
ful consideration of the scientific and medical knowledge and the evi-
dence available at the time of their dating.
The task of developing ESC/EACTS Guidelines also includes the
creation of educational tools and implementation programmes for
the recommendations including condensed pocket guideline ver-
sions, summary slides, booklets with essential messages, summary
cards for non-specialists and an electronic version for digital applica-
tions (smartphones, etc.). These versions are abridged and thus, if
needed, one should always refer to the full text version, which is
freely available via the ESC website and hosted on the EHJ website.
The National Societies of the ESC are encouraged to endorse, trans-
late and implement all ESC Guidelines. Implementation programmes
are needed because it has been shown that the outcome of disease
may be favourably influenced by the thorough application of clinical
recommendations.
Table 1 Classes of recommendations
Table 2 Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 
clinical trial or large non-randomized 
studies. 
Level of 
evidence C 
Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
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.Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC/EACTS
Guidelines fully into account when exercising their clinical judgment,
as well as in the determination and the implementation of preventive,
diagnostic or therapeutic medical strategies. However, the ESC/
EACTS Guidelines do not override in any way whatsoever the indi-
vidual responsibility of health professionals to make appropriate and
accurate decisions in consideration of each patient’s health condition
and in consultation with that patient or the patient’s caregiver where
appropriate and/or necessary. It is also the health professional’s
responsibility to verify the rules and regulations applicable to drugs
and devices at the time of prescription.
2. Introduction
2.1. Why do we need new guidelines on
valvular heart disease?
Since the previous version of the guidelines on the management of
VHD was published in 2012, new evidence has accumulated, particu-
larly on percutaneous interventional techniques and on risk stratifica-
tion with regard to timing of intervention in VHD. This made a
revision of the recommendations necessary. The current background
information and detailed discussion of the data for the following sec-
tion of these Guidelines can be found in ESC CardioMed.
2.2. Content of these guidelines
Decision making in VHD involves accurate diagnosis, timing of inter-
vention, risk assessment and, based on these, selection of the
most suitable type of intervention. These guidelines focus on acquired
VHD, are oriented towards management and do not deal with endo-
carditis or congenital valve disease, including pulmonary valve disease,
as separate guidelines have been published by the ESC on these topics.
2.3. New format of the guidelines
The new guidelines have been adapted to facilitate their use in clinical
practice and to meet readers’ demands by focusing on condensed,
clearly represented recommendations. At the end of each section,
Key points summarize the essentials. Gaps in evidence are listed to pro-
pose topics for future research. The guideline document is
harmonized with the simultaneously published chapter on
VHD of the ESC Textbook of Cardiology, which is freely
available by Internet access (https://academic.oup.com/
eurheartj/article-lookup/doi/10.1093/eurheartj/ehx391#
supplementary-data). The guidelines and the textbook are com-
plementary. Background information and detailed discussion of the
data that have provided the basis for the recommendations can be
found in the relevant book chapter.
2.4 How to use these guidelines
The Committee emphasizes that many factors ultimately determine
the most appropriate treatment in individual patients within a given
community. These factors include the availability of diagnostic equip-
ment, the expertise of cardiologists and surgeons, especially in the field
of valve repair and percutaneous intervention and, notably, the wishes
of well-informed patients. Furthermore, owing to the lack of evidence-
based data in the field of VHD, most recommendations are largely the
result of expert consensus opinion. Therefore, deviations from these
guidelines may be appropriate in certain clinical circumstances.
3. General comments
The aims of the evaluation of patients with VHD are to diagnose, quantify
and assess the mechanism of VHD as well as its consequences. Decision
making for intervention should be made by a ‘Heart Team’ with a partic-
ular expertise in VHD, comprising cardiologists, cardiac surgeons, imag-
ing specialists, anaesthetists and, if needed, general practitioners,
geriatricians and heart failure, electrophysiology or intensive care special-
ists. The ‘Heart Team’ approach is particularly advisable in the manage-
ment of high-risk patients and is also important for other subsets, such as
asymptomatic patients where the evaluation of valve reparability is a key
component in decision making. The essential questions in the evaluation
of a patient for valvular intervention are summarized in Table 3. The
current background information and detailed discussion of the
data for the following section of these Guidelines can be found in
ESC CardioMed.
3.1 Patient evaluation
Precise evaluation of the patient’s history and symptomatic status as
well as proper physical examination, in particular auscultation and
search for heart failure signs, are crucial for the diagnosis and manage-
ment of VHD. In addition, assessment of the extracardiac condition—
comorbidities and general condition—require particular attention.
Table 3 Essential questions in the evaluation of
patients for valvular intervention
VHD = valvular heart disease.
aLife expectancy should be estimated according to age, sex, comorbidities, and
country-specific life expectancy.
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..3.1.1 Echocardiography
Following adequate clinical evaluation, echocardiography is the key
technique used to confirm the diagnosis of VHD as well as to assess
its severity and prognosis. It should be performed and interpreted by
properly trained personnel.1
Echocardiographic criteria for the definition of severe valve steno-
sis and regurgitation are addressed in specific documents.2–4
Recommendations for stenotic lesions are indicated in the corre-
sponding sections and quantification of regurgitant lesions is summar-
ized in Table 4. An integrated approach including various criteria is
strongly recommended instead of referring to single measurements.
Echocardiography is also key to assess valve morphology and func-
tion as well as to evaluate the feasibility and indications of a specific
intervention.
Indices of left ventricular (LV) enlargement and function are strong
prognostic factors. Pulmonary artery pressure should be estimated
as well as right ventricular (RV) function.5 Transoesophageal echo-
cardiography (TOE) should be considered when transthoracic echo-
cardiography (TTE) is of suboptimal quality or when thrombosis,
prosthetic valve dysfunction or endocarditis is suspected.
Intraprocedural TOE is used to guide percutaneous mitral and aortic
valve interventions and to monitor the results of all surgical valve
operations and percutaneous valve implantation or repair.
3.1.2 Other non-invasive investigations
3.1.2.1 Stress testing
The primary purpose of exercise testing is to unmask the objective
occurrence of symptoms in patients who claim to be asymptomatic
or have non-specific symptoms, and is especially useful for risk stratifi-
cation in aortic stenosis.8 Exercise testing will also determine the
level of recommended physical activity, including participation in
sports.
Table 4 Echocardiographic criteria for the definition of severe valve regurgitation: an integrative approach (adapted
from Lancellotti et al.2,6,7)
CW = continuous wave; EDV = end-diastolic velocity; EROA = effective regurgitant orifice area; LA = left atrium/atrial; LV = left ventricle/ventricular; PISA = proximal isove-
locity surface area; RA = right atrium/right atrial; RV = right ventricle; TR = tricuspid regurgitation; TVI = time–velocity integral.
aAt a Nyquist limit of 50–60 cm/s.
bFor average between apical four- and two-chamber views.
cUnless other reasons for systolic blunting (atrial fibrillation, elevated atrial pressure).
dIn the absence of other causes of elevated LA pressure and of mitral stenosis.
eIn the absence of other causes of elevated RA pressure.
fPressure half-time is shortened with increasing LV diastolic pressure, vasodilator therapy, and in patients with a dilated compliant aorta, or lengthened in chronic aortic
regurgitation.
gBaseline Nyquist limit shift of 28 cm/s.
hDifferent thresholds are used in secondary mitral regurgitation where an EROA >20 mm2 and regurgitant volume >30 mL identify a subset of patients at increased risk of car-
diac events.
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Exercise echocardiography may identify the cardiac origin of dysp-
noea. The prognostic impact has been shown mainly for aortic steno-
sis and mitral regurgitation.9
The search for flow reserve (also called ‘contractile reserve’)
using low-dose dobutamine stress echocardiography is useful for
assessing aortic stenosis severity and for operative risk stratification
in low-gradient aortic stenosis with impaired LV function as well as to
assess the potential of reverse remodelling in patients with heart fail-
ure and functional mitral regurgitation after a mitral valve
procedure.10,11
3.1.2.2 Cardiac magnetic resonance
In patients with inadequate echocardiographic quality or discrepant
results, cardiac magnetic resonance (CMR) should be used to assess
the severity of valvular lesions, particularly regurgitant lesions, and to
assess ventricular volumes, systolic function, abnormalities of the
ascending aorta and myocardial fibrosis. CMR is the reference
method for the evaluation of RV volumes and function and is there-
fore particularly useful to evaluate the consequences of tricuspid
regurgitation.12
3.1.2.3 Computed tomography
Multislice computed tomography (MSCT) may contribute to evalua-
tion of the severity of valve disease, particularly in aortic stenosis13,14
and of the thoracic aorta. MSCT plays an important role in the
workup of patients with VHD considered for transcatheter interven-
tion, in particular transcatheter aortic valve implantation (TAVI), and
provides valuable information for pre-procedural planning. Owing to
its high negative predictive value, MSCT may be useful to rule out
coronary artery disease (CAD) in patients who are at low risk of
atherosclerosis.
3.1.2.4 Cinefluoroscopy
Cinefluoroscopy is particularly useful for assessing the kinetics of the
occluders of a mechanical prosthesis.
3.1.2.5 Biomarkers
B-type natriuretic peptide (BNP) serum levels are related to New
York Heart Association (NYHA) functional class and prognosis, par-
ticularly in aortic stenosis and mitral regurgitation.15 Natriuretic pep-
tides may be of value for risk stratification and timing of intervention,
particularly in asymptomatic patients.
3.1.3 Invasive investigations
3.1.3.1 Coronary angiography
Coronary angiography is indicated for the assessment of CAD
when surgery or an intervention is planned, to determine if concomi-
tant coronary revascularization is indicated (see following table of
recommendations).16 Alternatively, coronary computed tomography
(CT) can be used to rule out CAD in patients at low risk for the
condition.
Management of CAD in patients with VHD (adapted
from Windecker et al.16)
Recommendations Classa Levelb
Diagnosis of CAD
Coronary angiographyc is recommended
before valve surgery in patients with severe
VHD and any of the following:
• history of cardiovascular disease
• suspected myocardial ischaemiad
• LV systolic dysfunction
• in men >40 years of age and postmeno-
pausal women
• one or more cardiovascular risk factors.
I C
Coronary angiography is recommended in the
evaluation of moderate to severe secondary
mitral regurgitation.
I C
CT angiography should be considered as an
alternative to coronary angiography before
valve surgery in patients with severe VHD and
low probability of CAD or in whom conven-
tional coronary angiography is technically not
feasible or associated with a high risk.
IIa C
Indications for myocardial revascularization
CABG is recommended in patients with a pri-
mary indication for aortic/mitral valve surgery
and coronary artery diameter stenosis >_70%.e
I C
CABG should be considered in patients with a
primary indication for aortic/mitral valve sur-
gery and coronary artery diameter stenosis
>_50–70%.
IIa C
PCI should be considered in patients with a
primary indication to undergo TAVI and coro-
nary artery diameter stenosis >70% in proxi-
mal segments.
IIa C
PCI should be considered in patients with a
primary indication to undergo transcatheter
mitral valve interventions and coronary artery
diameter stenosis >70% in proximal segments.
IIa C
CABG = coronary artery bypass grafting; CAD = coronary artery disease; CT =
computed tomography; LV = left ventricular; MSCT = multislice computed
tomography; PCI = percutaneous coronary intervention; TAVI = transcatheter
aortic valve implantation; VHD = valvular heart disease.
aClass of recommendation.
bLevel of evidence.
cMSCT may be used to exclude CAD in patients who are at low risk of
atherosclerosis.
dChest pain, abnormal non-invasive testing.
e>_50% can be considered for left main stenosis.
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..3.1.3.2 Cardiac catheterization
The measurement of pressures and cardiac output or the assessment
of ventricular performance and valvular regurgitation by ventricular
angiography or aortography is restricted to situations where non-
invasive evaluation is inconclusive or discordant with clinical findings.
When elevated pulmonary pressure is the only criterion to support
the indication for surgery, confirmation of echo data by invasive
measurement is recommended.
3.1.4 Assessment of comorbidity
The choice of specific examinations to assess comorbidity is directed
by the clinical evaluation.
3.2 Risk stratification
Risk stratification applies to any sort of intervention and is required
for weighing the risk of intervention against the expected natural his-
tory of VHD as a basis for decision making. Most experience relates
to surgery and TAVI. The EuroSCORE I (http://www.euroscore.org/
calc.html) overestimates operative mortality and its calibration of risk
is poor. Consequently, it should no longer be used to guide decision
making. The EuroSCORE II and the Society of Thoracic Surgeons
(STS) score (http://riskcalc.sts.org/stswebriskcalc/#/) more accurately
discriminate high- and low-risk surgical patients and show better cali-
bration to predict postoperative outcome after valvular surgery.17,18
Scores have major limitations for practical use by insufficiently consid-
ering disease severity and not including major risk factors such as
frailty, porcelain aorta, chest radiation etc. While EuroSCORE I mark-
edly overestimates 30-day mortality and should therefore be
replaced by the better performing EuroSCORE II in this regard, it is
nevertheless provided in this document for comparison, as it has
been used in many TAVI studies/registries and may still be useful to
identify the subgroups of patients for decision between intervention
modalities and to predict 1-year mortality. Both scores have shown
variable results in predicting the outcomes of intervention in TAVI
but are useful for identifying low-risk patients for surgery. New
scores have been developed to estimate the risk of 30-day mortality
in patients undergoing TAVI, with better accuracy and discrimination,
albeit with numerous limitations.19,20
Experience with risk stratification is being accumulated for other
interventional procedures, such as mitral edge-to-edge repair. It
remains essential not to rely on a single risk score figure when assess-
ing patients or to determine unconditionally the indication and type
of intervention. Patient’s life expectancy, expected quality of life and
patient preference should be considered, as well as local resources.
The futility of interventions in patients unlikely to benefit from the
treatment has to be taken into consideration, particularly for TAVI
and mitral edge-to-edge repair.21 The role of the Heart Team is
essential to take all of these data into account and adopt a final deci-
sion on the best treatment strategy. Finally, the patient and family
should be thoroughly informed and assisted in their decision on the
best treatment option.22
3.3 Special considerations in elderly
patients
Poor mobility, as assessed by the 6-minute walk test, and oxygen
dependency are the main factors associated with increased mortality
after TAVI and other VHD treatments.23,24 The combination of
severe lung disease, postoperative pain from sternotomy or
thoracotomy and prolonged time under anaesthesia in patients
undergoing traditional surgical aortic valve replacement (SAVR) may
contribute to pulmonary complications. There is a gradual
relationship between the impairment of renal function and increased
mortality after valvular surgery, TAVI and transcatheter mitral edge-
to-edge repair,25 especially when glomerular filtration rate
is < 30 mL/min. Coronary, cerebrovascular and peripheral artery dis-
ease have a negative impact on early and late survival after surgery
and TAVI.22
Besides specific organ comorbidities, there is growing interest
in the assessment of frailty, an overall marker of impairment of
functional, cognitive and nutritional status. Frailty is associated
with increased morbidity and mortality after surgery and TAVI.26
The assessment of frailty should not rely on a subjective approach,
such as the ‘eyeball test’, but rather on a combination of different
objective estimates. Several tools are available for assessing
frailty.23,26,27
3.4 Endocarditis prophylaxis
Antibiotic prophylaxis should be considered for high-risk procedures
in patients with prosthetic valves, including transcatheter valves, or
with repairs using prosthetic material and those with previous epi-
sodes of infective endocarditis.28 Recommendations regarding dental
and cutaneous hygiene and strict aseptic measures during any invasive
procedures are advised in this population. Antibiotic prophylaxis
should be considered in dental procedures involving manipulation of
the gingival or periapical region of the teeth or manipulation of the
oral mucosa.28
3.5 Prophylaxis for rheumatic fever
Prevention of rheumatic heart disease should preferably be
oriented towards preventing the first attack of acute rheumatic fever.
Antibiotic treatment of group A Streptococcus sore throat is key in
primary prevention. In patients with rheumatic heart disease,
secondary long-term prophylaxis against rheumatic fever is recom-
mended. Lifelong prophylaxis should be considered in high-risk
patients according to the severity of VHD and exposure to group A
Streptococcus.29–31
3.6 Concept of the Heart Team and heart
valve centres
The main purpose of heart valve centres as centres of excellence in
the treatment of VHD is to deliver better quality of care. This is
achieved through greater volumes associated with specialization of
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training, continuing education and clinical interest. Specialization will
also result in timely referral of patients before irreversible adverse
effects occur and evaluation of complex VHD conditions.
Techniques with a steep learning curve may be performed with bet-
ter results in hospitals with high volumes and more experience.32
These main aspects are presented in Table 5.
A heart valve centre should have structured training programmes.32
Surgeons and cardiologists performing any valve intervention should
undergo focused training as part of their basic local board certification
training. Learning new techniques should take place through mentor-
ing to minimize the effects of the ‘learning curve’.
The relationship between case volume and outcomes for surgery
and transcatheter interventions is complex but should not be
denied.33–35 However, the precise numbers of procedures per indi-
vidual operator or hospital required to provide high-quality care
remain controversial and more scientific data are required before
solid recommendations can be provided. Nevertheless, standards for
provision of cardiac surgery that constitute the minimal core require-
ments have been released.36 Experience in the full spectrum of surgi-
cal procedures—including valve replacement; aortic root surgery;
mitral, tricuspid and aortic valve repair; repair of complicated valve
endocarditis such as root abscess; treatment of atrial fibrillation as
well as surgical myocardial revascularization—must be available. The
spectrum of interventional procedures in addition to TAVI should
include mitral valvuloplasty, mitral valve repair (edge-to-edge), clo-
sure of atrial septal defects, closure of paravalvular leaks and left atrial
(LA) appendage closure as well as percutaneous coronary interven-
tion (PCI). Expertise in interventional and surgical management of
vascular diseases and complications must be available.
Comprehensive recording of performance and patient outcome data
at the level of the given heart valve centre is essential, as well as par-
ticipation in national or ESC/EACTS registries.
3.7 Management of associated conditions
3.7.1 Coronary artery disease
The use of stress tests to detect CAD associated with severe valvular
disease is discouraged because of their low diagnostic value and
potential risks. A summary of the management of associated CAD is
given in section 3.1.3.1 (see table of recommendations on the man-
agement of CAD in patients with VHD) and is detailed in specific
guidelines.16
3.7.2 Atrial fibrillation
Non-vitamin K antagonist oral anticoagulants (NOACs) are
approved only for non-valvular atrial fibrillation, but there is no uni-
form definition of this term.37 Recent subgroup analyses of random-
ized trials on atrial fibrillation support the use of rivaroxaban,
apixaban, dabigatran and edoxaban in patients with aortic stenosis,
aortic regurgitation or mitral regurgitation presenting with atrial fibril-
lation.38–41 The use of NOACs is discouraged in patients who have
atrial fibrillation associated with moderate to severe mitral stenosis,
given the lack of data and the particularly high thromboembolic risk.
Despite the absence of data, NOACs may be used in patients who
have atrial fibrillation associated with an aortic bioprosthesis
>3 months after implantation but are strictly contraindicated in
patients with any mechanical prostheses.42,43
Surgical ablation of atrial fibrillation combined with mitral valve
surgery is effective in reducing the incidence of atrial fibrillation, but
at the expense of more frequent pacemaker implantation, and has no
impact on short-term survival.44 Surgical ablation should be consid-
ered in patients with symptomatic atrial fibrillation and may be con-
sidered in patients with asymptomatic atrial fibrillation if feasible with
minimal risk. The decision should factor in other important variables,
such as age, the duration of atrial fibrillation and LA size. Surgical exci-
sion or external clipping of the LA appendage may be considered
combined with valvular surgery, although there is no evidence that it
decreases thromboembolic risk. For patients with atrial fibrillation
and risk factors for stroke, long-term oral anticoagulation is currently
recommended, although surgical ablation of atrial fibrillation and/or
surgical LA appendage excision or exclusion may have been per-
formed.37 Recommendations for the management of atrial fibrillation
in VHD are summarized in the following table.
Table 5 Recommended requirements of a heart valve
centre (modified from Chambers et al.32)
3D = three-dimensional; CT = computed tomography; MRI = magnetic reso-
nance imaging; TOE = transoesophageal echocardiography.
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Key points
• Precise evaluation of the patient’s history and symptomatic status
as well as proper physical examination are crucial for the diagno-
sis and management of VHD.
• Echocardiography is the key technique to diagnose VHD and
assess its severity and prognosis. Other non-invasive investiga-
tions such as stress testing, CMR, CT, fluoroscopy and bio-
markers are complementary, and invasive investigation beyond
preoperative coronary angiography is restricted to situations
where non-invasive evaluation is inconclusive.
• Risk stratification is essential for decision making to weigh the
risk of intervention against the expected natural history of VHD.
• Decision making in elderly patients requires special considera-
tions, including life expectancy and expected quality of life, with
regards to comorbidities and general condition (frailty).
• Heart valve centres with highly specialized multidisciplinary teams,
comprehensive equipment and sufficient volumes of procedures are
required to deliver high-quality care and provide adequate training.
• NOACs may be used in patients with atrial fibrillation and aortic
stenosis, aortic regurgitation, mitral regurgitation or aortic bio-
prostheses >3 months after implantation but are contraindicated
in mitral stenosis and mechanical valves.
Gaps in evidence
• Better tools for risk stratification need to be developed, particu-
larly for the decision between surgery and catheter intervention
and for the avoidance of futile interventions.
• Minimum volumes of procedures per operator and per hospital
that are required to achieve optimal treatment results need to
be defined.
• The safety and efficacy of NOACs in patients with surgical or
transcatheter bioprostheses in the first 3 months after implanta-
tion should be studied.
4. Aortic regurgitation
Aortic regurgitation can be caused by primary disease of the aortic
valve cusps and/or abnormalities of the aortic root and ascending
aortic geometry. Degenerative tricuspid and bicuspid aortic regurgi-
tation are the most common aetiologies in Western countries,
accounting for approximately two-thirds of the underlying aetiology
of aortic regurgitation in the Euro Heart Survey on VHD.47 Other
causes include infective and rheumatic endocarditis. Acute severe
aortic regurgitation is mostly caused by infective endocarditis and less
frequently by aortic dissection. The current background information
and detailed discussion of the data for the following section of these
Guidelines can be found in ESC CardioMed.
4.1 Evaluation
4.1.1 Echocardiography
Echocardiography (TTE/TOE) is the key examination to describe
valve anatomy, quantify aortic regurgitation, evaluate its mechanisms,
define the morphology of the aorta and determine the feasibility of
valve-sparing aortic surgery or valve repair.48,49
Essential aspects of this evaluation include
• Assessment of valve morphology: tricuspid, bicuspid, unicuspid or
quadricuspid valve.
• Determination of the direction of the aortic regurgitation jet in
the long-axis view (central or eccentric) and its origin in the
short-axis view (central or commissural).
• Identification of the mechanism, following the same
principle as for mitral regurgitation: normal cusps but insuffi-
cient coaptation due to dilatation of the aortic root with
central jet (type 1), cusp prolapse with eccentric jet (type 2)
or retraction with poor cusp tissue quality and large central
or eccentric jet (type 3).48
• Quantification of aortic regurgitation should follow an integrated
approach considering all qualitative, semi-quantitative and quanti-
tative parameters2,6 (Table 4).
• Measurement of LV function and dimensions. Indexing LV diame-
ters for body surface area (BSA) is recommended in patients
with small body size (BSA <1.68 m2).50 New parameters
Management of atrial fibrillation in patients with VHD
Recommendations Classa Levelb
Anticoagulation
NOACs should be considered as an alterna-
tive to VKAs in patients with aortic stenosis,
aortic regurgitation and mitral regurgitation
presenting with atrial fibrillation.38–41
IIa B
NOACs should be considered as an alterna-
tive to VKAs after the third month of
implantation in patients who have atrial
fibrillation associated with a surgical or
transcatheter aortic valve bioprosthesis.
IIa C
The use of NOACs is not recommended in
patients with atrial fibrillation and moderate
to severe mitral stenosis.
III C
NOACS are contraindicated in patients
with a mechanical valve.45
III B
Surgical interventions
Surgical ablation of atrial fibrillation should
be considered in patients with symptomatic
atrial fibrillation who undergo valve
surgery.37
IIa A
Surgical ablation of atrial fibrillation may be
considered in patients with asymptomatic
atrial fibrillation who undergo valve surgery,
if feasible, with minimal risk.
IIb C
Surgical excision or external clipping of the
LA appendage may be considered in
patients undergoing valve surgery.46
IIb B
LA = left atrial; NOAC = non-vitamin K antagonist oral anticoagulant; VHD =
valvular heart disease; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
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obtained by three-dimensional (3D) echocardiography, tissue
Doppler and strain rate imaging may be useful, particularly in
patients with borderline left ventricular ejection fraction (LVEF),
where they may help in the decision for surgery.51
• Measurement of the aortic root and ascending aorta in the 2-
dimensional (2D) mode at four levels: annulus, sinuses of
Valsalva, sinotubular junction and tubular ascending aorta.52
Measurements are taken in the parasternal long-axis view from
leading edge to leading edge at end diastole, except for the aortic
annulus, which is measured in mid systole. As it will have surgical
consequences, it is important to differentiate three phenotypes
of the ascending aorta: aortic root aneurysms (sinuses of Valsalva
>45 mm), tubular ascending aneurysm (sinuses of Valsalva <40–
45 mm) and isolated aortic regurgitation (all diameters <40 mm).
The calculation of indexed values has been recommended to
account for body size.53
• Definition of the anatomy of the aortic valve cusps and assess-
ment of valve reparability should be provided by preoperative
TOE if aortic valve repair or a valve-sparing surgery of the aortic
root is considered.
• Intraoperative evaluation of the surgical result by TOE is manda-
tory in patients in whom the aortic valve is preserved or repaired
in the procedure.
4.1.2 Computed tomography and cardiac magnetic
resonance
CMR should be used to quantify the regurgitant fraction when
echocardiographic measurements are equivocal. In patients with
aortic dilatation, gated MSCT is recommended to assess the maxi-
mum diameter. CMR can be used for follow-up, but indication for
surgery should preferably be based on CT measurements.
Different methods of aortic measurements have been reported
and this may result in diameter discrepancies of 2–3 mm that could
influence therapeutic management. To improve reproducibility, it is
recommended to measure diameters using the inner-inner edge
technique at end diastole on the strictly transverse plane by double
oblique reconstruction perpendicular to the axis of blood flow of
the corresponding segment. Diameters at the annulus, sinus of
Valsalva, sinotubular junction, tubular ascending aorta and aortic
arch level should be reported. Maximum root diameter should be
taken from sinus to sinus rather than sinus to commissure diame-
ter, as it correlates more closely to long-axis leading edge to leading
edge echo maximum diameters.54,55
4.2 Indications for intervention
Acute aortic regurgitation may require urgent surgery. It is primarily
caused by infective endocarditis and aortic dissections. Specific guide-
lines deal with these entities.28,56 The indications for intervention in
chronic aortic regurgitation are summarized on the next page (rec-
ommendations on indications for surgery in severe aortic regurgita-
tion and aortic root disease) and in Figure 1 and may be related to
symptoms, status of the LV or dilatation of the aorta.
In symptomatic patients, surgery is recommended irrespective of
the LVEF value, except for extreme cases, as long as aortic regurgita-
tion is severe and the operative risk is not prohibitive.57
In asymptomatic patients with severe aortic regurgitation, impair-
ment of LV function (ejection fraction <_50%) and LV enlargement
with an LV end-diastolic diameter (LVEDD) >70 mm or left ventricu-
lar end-systolic diameter (LVESD) >50 mm are associated with
Figure 1 Management of aortic regurgitation. AR = aortic regur-
gitation; BSA = body surface area; LVEDD = left ventricle end-dia-
stolic diameter; LVEF = left ventricular ejection fraction; LVESD =
left ventricle end-systolic diameter.
aSee table of recommendations on indications for surgery in
severe aortic regurgitation and aortic root disease for
definition.
bSurgery should also be considered if significant changes in LV
or aortic size occur during follow-up (see table of recommen-
dations on indications for surgery in severe aortic regurgita-
tion and aortic root disease in section 4.2).
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worse outcome and surgery should therefore be pursued when
these cut-offs are reached.58 In patients with small body size, LVESD
should be related to BSA and a cut-off of 25 mm/m2 BSA appears to
be more appropriate.50 In patients not reaching the thresholds for
surgery, close follow-up is needed and exercise testing should be per-
formed to identify borderline symptomatic patients. In truly asympto-
matic patients, regular assessment of LV function and physical
condition are crucial to identify the optimal time for surgery. A rapid
progression of ventricular dimensions or decline in ventricular func-
tion on serial testing is a reason to consider surgery.
In patients with a dilated aorta, the rationale for surgery has been
best defined in patients with Marfan syndrome and root dilation.59
Root aneurysms need to have root replacement, with or without
preservation of the native aortic valve, but definitely with coronary
reimplantation. In contrast, tubular ascending aortic aneurysms
require only a supracommissural tube graft replacement without
coronary reimplantation. In patients with aortic diameters border-
line for aortic surgery, the family history, age and anticipated risk of
the procedure should be taken into consideration. In individuals
with a bicuspid aortic valve and no significant valve regurgitation,
prophylactic surgery should be considered with aortic diameters
>_55 mm or >_ 50 mm when additional risk factors or coarctation
are present (see table of recommendations on indications for sur-
gery in severe aortic regurgitation and aortic root disease). Surgery
is indicated in all patients with Marfan syndrome and a maximal
aortic diameter >_50 mm. In patients with Marfan syndrome and
additional risk factors and in patients with a TGFBR1 or TGFBR2
mutation (including Loeys–Dietz syndrome), surgery should be
considered at a maximal aortic diameter >_45 mm.60 In the latter
group, women with low BSA, patients with a TGFBR2 mutation or
patients with severe extra-aortic features appear to be at particu-
larly high risk and surgery may be considered already at a lower
threshold of 40 mm.60 In aortic roots >_55 mm, surgery should be
considered irrespective of the degree of aortic regurgitation and
type of valve pathology.61 For patients who have an indication for
aortic valve surgery, an aortic diameter >_45 mm is considered to
indicate concomitant surgery of the aortic root or tubular ascend-
ing aorta. The patient’s stature, the aetiology of the valvular disease
(bicuspid valve) and the intraoperative shape and wall thickness of
the ascending aorta should be taken into account for individual
decisions.
Although valve replacement is the standard procedure in the
majority of patients with aortic regurgitation, valve repair or valve-
sparing surgery should be considered in patients with pliable non-
calcified tricuspid or bicuspid valves who have a type I (enlarge-
ment of the aortic root with normal cusp motion) or type II (cusp
prolapse) mechanism of aortic regurgitation.6,48,49 In experienced
centres, valve-sparing root replacement and valve repair, when fea-
sible, yield good long-term results with low rates of valve-related
events as well as better quality of life.62–65 The choice of the surgi-
cal procedure should be adapted to the experience of the team,
the presence of an aortic root aneurysm, characteristics of the
cusps, life expectancy and desired anticoagulation status. Patients
in whom the Heart Team identifies the aortic valve to be repairable
should be referred to appropriate surgical teams for the
procedure.
Indications for surgery in (A) severe aortic regurgitation
and (B) aortic root disease (irrespective of the severity
of aortic regurgitation)
Indications for surgery Classa Levelb
A. Severe aortic regurgitation
Surgery is indicated in symptomatic patients.57,58,66,67 I B
Surgery is indicated in asymptomatic patients with resting
LVEF <_50%.57,58
I B
Surgery is indicated in patients undergoing CABG or sur-
gery of the ascending aorta or of another valve.
I C
Heart Team discussion is recommended in selected
patientsc in whom aortic valve repair may be a feasible
alternative to valve replacement.
I C
Surgery should be considered in asymptomatic patients
with resting ejection fraction >50% with severe LV dilata-
tion: LVEDD >70 mm or LVESD >50 mm (or LVESD
>25 mm/m2 BSA in patients with small body size).58,66
IIa B
B. Aortic root or tubular ascending aortic aneurysmd (irrespective of the
severity of aortic regurgitation)
Aortic valve repair, using the reimplantation or remodel-
ling with aortic annuloplasty technique, is recommended in
young patients with aortic root dilation and tricuspid aortic
valves, when performed by experienced surgeons.
I C
Surgery is indicated in patients with Marfan syndrome who
have aortic root disease with a maximal ascending aortic
diameter >_50 mm.
I C
Surgery should be considered in patients who have aortic
root disease with maximal ascending aortic diameter:
• >_45 mm in the presence of Marfan syndrome and
additional risk factorse or patients with a TGFBR1 or
TGFBR2 mutation (including Loeys–Dietz syndrome).f
• >_50 mm in the presence of a bicuspid valve with
additional risk factorse or coarctation.
• >_55 mm for all other patients.
IIa C
IIa C
IIa
C
IIa C
When surgery is primarily indicated for the aortic valve,
replacement of the aortic root or tubular ascending aorta
should be considered when >_45 mm, particularly in the
presence of a bicuspid valve.g
IIa C
BSA = body surface area; CABG = coronary artery bypass grafting; CT = com-
puted tomography; ECG = electrocardiogram; LV = left ventricular; LVEDD =
left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction;
LVESD = left ventricular end-systolic diameter.
aClass of recommendation.
bLevel of evidence.
cPatients with pliable non-calcified tricuspid or bicuspid valves who have a type I
(enlargement of the aortic root with normal cusp motion) or type II (cusp pro-
lapse) mechanism of aortic regurgitation.6,48,49
dFor clinical decision making, dimensions of the aorta should be confirmed by
ECG-gated CT measurement.
eFamily history of aortic dissection (or personal history of spontaneous vascular
dissection), severe aortic regurgitation or mitral regurgitation, desire for preg-
nancy, systemic hypertension and/or aortic size increase >3 mm/year (on
repeated measurements using the same ECG-gated imaging technique measured
at the same level of the aorta with side-by-side comparison and confirmed by
another technique).
fA lower threshold of 40 mm may be considered in women with low BSA, in
patients with a TGFBR2 mutation or in patients with severe extra-aortic
features.60
gConsidering age, BSA, aetiology of the valvular disease, presence of a bicuspid
aortic valve and intraoperative shape and thickness of the ascending aorta.
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4.3 Medical therapy
Medical therapy can provide symptomatic improvement in individuals
with chronic severe aortic regurgitation in whom surgery is not feasi-
ble. In patients who undergo surgery but continue to suffer from
heart failure or hypertension, angiotensin-converting enzyme (ACE)
inhibitors, angiotensin receptor blockers (ARBs) and beta-blockers
are useful.68,69
In patients with Marfan syndrome, beta-blockers and/or losartan
may slow aortic root dilatation and reduce the risk of aortic com-
plications and should be considered before and after surgery.70–72 By
analogy, while there are no studies that provide evidence, it is com-
mon clinical practice to advise beta-blocker or losartan therapy in
patients with bicuspid aortic valve if the aortic root and/or ascending
aorta is dilated.
Women with Marfan syndrome and an aortic diameter >45 mm are
strongly discouraged from becoming pregnant without prior repair
because of the high risk of dissection. Although an aortic diameter
<40 mm is rarely associated with aortic dissection, a completely safe
diameter does not exist. With an aorta between 40 and 45 mm, pre-
vious aortic growth and family history are important for advising preg-
nancy with or without aortic repair.73 Although the actual risk of
dissection is not well-documented in the setting of bicuspid valves,
counselling against pregnancy is recommended in the setting of aortic
diameters >50 mm.74
The level of physical and sports activity in the presence of a dilated
aorta remains a matter of clinical judgement in the absence of evi-
dence. Current guidelines are very restrictive, particularly regarding
isometric exercise, to avoid a catastrophic event.75 This attitude is
clearly justified in the presence of connective tissue disease.
Given the family risk of thoracic aortic aneurysms, screening and
referral for genetic testing of the patient’s first-degree relatives with
appropriate imaging studies is indicated in patients with connective
tissue disease. For patients with bicuspid valves it is appropriate to
have an echocardiographic screening of first-degree relatives.
4.4 Serial testing
All asymptomatic patients with severe aortic regurgitation and nor-
mal LV function should be seen for follow-up at least every year. In
patients with a first diagnosis, or if LV diameter and/or ejection frac-
tion show significant changes or come close to thresholds for sur-
gery, follow-up should be continued at 3–6-month intervals. In
inconclusive cases, BNP may be helpful, as its elevation during follow-
up has been related to deterioration of LV function.76 Patients with
mild to moderate aortic regurgitation can be reviewed on a yearly
basis and echocardiography performed every 2 years.
If the ascending aorta is dilated (>40 mm) it is recommended to
perform CT or CMR. Follow-up assessment of the aortic dimension
should be performed using echocardiography and/or CMR. Any
increase >3 mm should be validated by CT angiography/CMR and
compared to baseline data.
4.5 Special patient populations
If aortic regurgitation requiring surgery is associated with severe mitral
regurgitation, both should be addressed during the same operation.
In patients with moderate aortic regurgitation who undergo coro-
nary artery bypass grafting (CABG) or mitral valve surgery, the
decision to treat the aortic valve is controversial, as data show that
progression of moderate aortic regurgitation is very slow in patients
without aortic dilatation.77 The Heart Team should decide based on
the aetiology of aortic regurgitation, other clinical factors, the life
expectancy of the patient and the patient’s operative risk.
Key points
• The evaluation of aortic regurgitation requires consideration of
valve morphology and the mechanism and severity of regurgita-
tion, including careful assessment of aortic dilatation.
• In asymptomatic patients with severe aortic regurgitation, careful
follow-up of symptomatic status and LV size and function is
mandatory.
• The strongest indication for valve surgery is the presence of
symptoms (spontaneous or on exercise testing) and/or the
documentation of LVEF <50% and/or end-systolic diameter
>50 mm.
• In patients with a dilated aorta, definition of the aortic pathology
and accurate measurements of aortic diameters are crucial to
guide the timing and type of surgery.
• Aortic valve repair and valve-sparing aortic surgery instead of
aortic valve replacement should be considered in selected cases
in experienced centres.
Gaps in evidence
• The impact of earlier markers of LV dysfunction on postopera-
tive outcome requires further research.
• Criteria for the decision between valve replacement and valve
repair must still be refined.
• Potential differences in the risk of aortic complications depending
on subtypes of aortic aneurysms (site and morphology) should
be studied.
• The effect of medical treatment on aortic enlargement in patients
with bicuspid aortic valve needs to be studied.
5. Aortic stenosis
Aortic stenosis is the most common primary valve disease leading to
surgery or catheter intervention in Europe and North America, with
a growing prevalence due to the ageing population. The current back-
ground information and detailed discussion of the data for the follow-
ing section of these Guidelines can be found in ESC CardioMed.
5.1 Evaluation
5.1.1 Echocardiography
Echocardiography is the key diagnostic tool. It confirms the presence
of aortic stenosis; assesses the degree of valve calcification, LV func-
tion and wall thickness; detects the presence of other associated
valve disease or aortic pathology and provides prognostic informa-
tion. Doppler echocardiography is the preferred technique for
assessing the severity of aortic stenosis.4
Figure 2 and Table 6 provide a practical stepwise approach for the
assessment of aortic stenosis severity. Details can be found in a
recent position paper from the European Association of
Cardiovascular Imaging.4
Although valve area represents, from a theoretical perspective, the
ideal measurement for assessing the severity of aortic stenosis, it has
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Figure 2 Stepwise integrated approach for the assessment of aortic stenosis severity (modified from Baumgartner et al4). aHigh flow may be reversi-
ble in settings such as anaemia, hyperthyroidism, arteriovenous shunts. bPseudosevere AS is defined by an increase to an AVA >1.0cm2 with flow
normalization.
DPm = mean transvalvular pressure gradient; AS = aortic stenosis; AVA = aortic valve area; CT = computed tomography; EF = ejection
fraction; LVEF = left ventricular ejection fraction; SVi = stroke volume index; Vmax = peak transvalvular velocity.
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..technical limitations in clinical practice. It must, for clinical decision
making, always be considered together with flow rate, mean pressure
gradient (the most robust measurement), ventricular function, size
and wall thickness, degree of valve calcification, blood pressure and
functional status. Hypertensive patients should be reassessed when
normotensive.4 Four categories of aortic stenosis can be defined:
• High-gradient aortic stenosis (valve area <1 cm2, mean gradient
>40 mmHg). Severe aortic stenosis can be assumed irrespective
of whether LVEF and flow are normal or reduced.
• Low-flow, low-gradient aortic stenosis with reduced ejection
fraction [valve area <1 cm2, mean gradient <40 mmHg, ejection
fraction <50%, stroke volume index (SVi) <_35 mL/m2]. Low-dose
dobutamine echocardiography is recommended in this setting to
distinguish truly severe aortic stenosis from pseudosevere aortic
stenosis, which is defined by an increase to an aortic valve area
(AVA) of > 1.0 cm2 with flow normalization. In addition, the pres-
ence of flow reserve (also termed contractile reserve; increase of
stroke volume >20%) has prognostic implications because it is
associated with better outcome.10,78
• Low-flow, low-gradient aortic stenosis with preserved ejection
fraction (valve area <1 cm2, mean gradient <40 mmHg, ejection
fraction >_50%, SVi <_35 mL/m2). This is typically encountered in
the elderly and is associated with small ventricular size, marked
LV hypertrophy and frequently a history of hypertension.79,80
The diagnosis of severe aortic stenosis in this setting remains
challenging and requires careful exclusion of measurement errors
and other reasons for such echocardiographic findings (Table 6).
The degree of valve calcification by MSCT is related to aortic
stenosis severity and outcome.13,14,81 Its assessment has there-
fore gained increasing importance in this setting.
• Normal-flow, low-gradient aortic stenosis with preserved ejec-
tion fraction (valve area <1 cm2, mean gradient <40 mmHg, ejec-
tion fraction >_50%, SVi >35 mL/m2). These patients will in
general have only moderate aortic stenosis.14,82–84
5.1.2 Additional diagnostic aspects, including assessment
of prognostic parameters
Exercise testing is recommended in physically active patients for
unmasking symptoms and for risk stratification of asymptomatic
patients with severe aortic stenosis.85
Exercise stress echocardiography may provide prognostic infor-
mation in asymptomatic severe aortic stenosis by assessing the
increase in mean pressure gradient and change in LV function during
exercise.86
TOE provides additional evaluation of concomitant mitral valve
abnormalities. It has gained importance in the assessment before
TAVI and after TAVI or surgical procedures.87
MSCT and CMR provide additional information on the dimensions
and geometry of the aortic root and ascending aorta and the extent
of calcification. It has become particularly important for the quantifi-
cation of valve calcification when assessing aortic stenosis severity in
low-gradient aortic stenosis.13,14,81 CMR may be useful for the detec-
tion and quantification of myocardial fibrosis, providing additional
prognostic information regardless of the presence of CAD.88
Natriuretic peptides have been shown to predict symptom-free
survival and outcome in normal and low-flow severe aortic steno-
sis89,90 and may be useful in asymptomatic patients to determine opti-
mal timing of intervention.
Retrograde LV catheterization to assess the severity of aortic
stenosis is no longer routinely performed. Its use is restricted to
patients with inconclusive non-invasive investigations.
5.1.3 Diagnostic workup before transcatheter aortic valve
implantation
MSCT is the preferred imaging tool to assess the anatomy and dimen-
sions of the aortic root, size and shape of the aortic valve annulus, its
distance to the coronary ostia, the distribution of calcifications and
Table 6 Criteria that increase the likelihood of severe aortic stenosis in patients with AVA <1.0 cm2 and mean gra-
dient <40 mmHg in the presence of preserved ejection fraction (modified from Baumgartner et al.4)
3D = three-dimensional; AVA = aortic valve area; CMR = cardiovascular magnetic resonance; LV = left ventricular; LVOT = left ventricular outflow tract; MSCT = multislice
computed tomography; SVi = stroke volume index; TOE = transoesophageal echocardiography.
aHaemodynamics measured when the patient is normotensive.
bValues are given in arbitrary units using Agatston method for quantification of valve calcification.
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the number of aortic valve cusps. It is essential to evaluate the feasibil-
ity of the various access routes, as this provides information on mini-
mal luminal diameters, atherosclerotic plaque burden, the presence
of aneurysms or thrombi, vessel tortuosity and thoracic and LV apex
anatomy. CMR—as an alternative technique—is, in this context, infe-
rior to MSCT with regards to assessment of inner vessel dimensions
and calcifications. 3D TOE can be used to determine aortic annulus
dimensions but remains more operator- and image quality–depend-
ent than MSCT. However, TOE is an important tool for monitoring
the procedure and evaluating the results, especially if complications
occur.
5.2 Indications for intervention
The indications for aortic valve interventions are summarized on the
next page (see table of indications for intervention in aortic stenosis
and recommendations for the choice of intervention mode) and in
Table 7 and are illustrated in Figure 3.
Figure 3 Management of severe aortic stenosis. AS = aortic stenosis; LVEF = left ventricular ejection fraction; SAVR = surgical aortic valve replace-
ment; TAVI = transcatheter aortic valve implantation.
aSee Figure 2 and Table 6 for the definition of severe AS.
bSurgery should be considered (IIa C) if one of the following is present: peak velocity >5.5 m/s; severe valve calcification þ peak velocity
progression >_0.3 m/s per year; markedly elevated neurohormones (>threefold age- and sex-corrected normal range) without other
explanation; severe pulmonary hypertension (systolic pulmonary artery pressure >60 mmHg).
cSee Table 7 and Table of Recommendations in section 5.2 Indications for interventions in aortic stenosis.
2754 ESC/EACTS Guidelines
Downloaded from https://academic.oup.com/eurheartj/article-abstract/38/36/2739/4095039
by University of Zurich user
on 03 April 2018
Indications for intervention in aortic stenosis and recommendations for the choice of intervention mode
A) Symptomatic aortic stenosis Classa Levelb
Intervention is indicated in symptomatic patients with severe, high-gradient aortic stenosis (mean gradient >_40 mmHg or peak velocity
>_4.0 m/s).91–93
I B
Intervention is indicated in symptomatic patients with severe low-flow, low-gradient (<40 mmHg) aortic stenosis with reduced ejection frac-
tion and evidence of flow (contractile) reserve excluding pseudosevere aortic stenosis.
I C
Intervention should be considered in symptomatic patients with low-flow, low-gradient (<40 mmHg) aortic stenosis with normal ejection
fraction after careful confirmation of severe aortic stenosisc (see Figure 2 and Table 6).
IIa C
Intervention should be considered in symptomatic patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction without
flow (contractile) reserve, particularly when CT calcium scoring confirms severe aortic stenosis.
IIa C
Intervention should not be performed in patients with severe comorbidities when the intervention is unlikely to improve quality of life or
survival.
III C
B) Choice of intervention in symptomatic aortic stenosis
Aortic valve interventions should only be performed in centres with both departments of cardiology and cardiac surgery on site and with
structured collaboration between the two, including a Heart Team (heart valve centres).
I C
The choice for intervention must be based on careful individual evaluation of technical suitability and weighing of risks and benefits of each
modality (aspects to be considered are listed in Table 7). In addition, the local expertise and outcomes data for the given intervention must
be taken into account.
I C
SAVR is recommended in patients at low surgical risk (STS or EuroSCORE II < 4% or logistic EuroSCORE I < 10%d and no other risk factors
not included in these scores, such as frailty, porcelain aorta, sequelae of chest radiation).93
I B
TAVI is recommended in patients who are not suitable for SAVR as assessed by the Heart Team.91,94 I B
In patients who are at increased surgical risk (STS or EuroSCORE II >_ 4% or logistic EuroSCORE I >_ 10%d or other risk factors not included
in these scores such as frailty, porcelain aorta, sequelae of chest radiation), the decision between SAVR and TAVI should be made by the
Heart Team according to the individual patient characteristics (see Table 7), with TAVI being favoured in elderly patients suitable for transfe-
moral access.91,94–102
I B
Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients or in patients with sympto-
matic severe aortic stenosis who require urgent major non-cardiac surgery.
IIb C
Balloon aortic valvotomy may be considered as a diagnostic means in patients with severe aortic stenosis or other potential causes for symp-
toms (i.e. lung disease) and in patients with severe myocardial dysfunction, pre-renal insufficiency or other organ dysfunction that may be
reversible with balloon aortic valvotomy when performed in centres that can escalate to TAVI.
IIb C
C) Asymptomatic patients with severe aortic stenosis (refers only to patients eligible for surgical valve replacement)
SAVR is indicated in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF <50%) not due to another cause. I C
SAVR is indicated in asymptomatic patients with severe aortic stenosis and an abnormal exercise test showing symptoms on exercise clearly
related to aortic stenosis.
I C
SAVR should be considered in asymptomatic patients with severe aortic stenosis and an abnormal exercise test showing a decrease in blood
pressure below baseline.
IIa C
SAVR should be considered in asymptomatic patients with normal ejection fraction and none of the above-mentioned exercise test abnor-
malities if the surgical risk is low and one of the following findings is present:
• Very severe aortic stenosis defined by a Vmax >5.5 m/s
• Severe valve calcification and a rate of Vmax progression >_0.3 m/s/year
• Markedly elevated BNP levels (>threefold age- and sex-corrected normal range) confirmed by repeated measurements
without other explanations
• Severe pulmonary hypertension (systolic pulmonary artery pressure at rest >60 mmHg confirmed by invasive measure-
ment) without other explanation.
IIa C
D) Concomitant aortic valve surgery at the time of other cardiac/ascending aorta surgery
SAVR is indicated in patients with severe aortic stenosis undergoing CABG or surgery of the ascending aorta or of another valve. I C
Continued
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..5.2.1 Indications for intervention in symptomatic aortic
stenosis
Early therapy should be strongly recommended in all symptomatic
patients with severe aortic stenosis because of their dismal spontane-
ous prognosis. The only exceptions are patients with severe comor-
bidities indicating a survival of < 1 year and patients in whom severe
comorbidities or their general condition at an advanced age make it
unlikely that the intervention will improve quality of life or survival.
As long as the mean gradient remains >40mmHg, there is virtually no
lower ejection fraction limit for intervention, whether surgery or TAVI.
The management of patients with low-gradient aortic stenosis is more
challenging:
• In patients with low-flow, low-gradient aortic stenosis and
reduced ejection fraction in whom the depressed ejection frac-
tion is predominantly caused by excessive afterload, LV function
usually improves after intervention.10,104 Conversely, improve-
ment in LV function after intervention is uncertain if the primary
cause is scarring due to extensive myocardial infarction or cardio-
myopathy. Intervention is definitely advised when severe aortic
stenosis is confirmed at increasing flow (true severe aortic steno-
sis),10 while patients who are classified as having pseudosevere
aortic stenosis at increasing flow should receive conventional
treatment for heart failure.105 Although the outcome of patients
without flow reserve is compromised by a higher operative mor-
tality, SAVR (as well as TAVI) has also been shown to improve
ejection fraction and clinical status in such patients.10,78,104
Decision making should take into account the clinical condition
(in particular the comorbidities), the degree of valve calcification,
the extent of coronary disease and the feasibility of concomitant
or staged revascularization. The ability to identify patients with
severe aortic stenosis in this subgroup by CT calcium scoring and
the availability of TAVI have lowered the threshold to intervene.
• Patients with low-flow, low-gradient aortic stenosis and pre-
served ejection fraction are the most challenging subgroup. Data
on their natural history and outcome after surgical or catheter
intervention remain controversial.80,83,84 In such cases, interven-
tion should only be performed when symptoms are present and
if comprehensive evaluation suggests significant valve obstruction
(see Figure 2 and Table 6).
• Patients with normal-flow, low-gradient aortic stenosis and pre-
served ejection fraction data should be re-evaluated. If normal
flow and low gradient are confirmed, these patients will, in gen-
eral, not have severe aortic stenosis and do not benefit from
intervention.82,83
5.2.2 Choice of intervention mode in symptomatic aortic
stenosis
The choice of the intervention mode should take into account the
cardiac and extracardiac characteristics of the patient, the individual
risk of surgery, which is assessed by the judgement of the Heart
Team in addition to scores, the feasibility of TAVI and the local expe-
rience and outcome data.
Data on TAVI are still very limited for patients <75 years of age
and for surgical low-risk patients, in whom SAVR remains the refer-
ence method. It has to be emphasized that younger patients differ
with regard to anatomy (more bicuspid valves), which affects the
results of TAVI (bicuspid valves were also in general excluded in clini-
cal trials), and that long-term durability data for TAVI prosthetic
valves are still lacking.
Available data from randomized controlled trials and large registries
in elderly patients at increased surgical risk show that TAVI is superior
in terms of mortality to medical therapy in extreme-risk patients,91
non-inferior or superior to surgery in high-risk patients94–97 and non-
inferior to surgery and even superior when transfemoral access is pos-
sible in intermediate-risk patients.98–102 In the two large studies on
intermediate risk, the mean ages of patients were 82 and 80 years,99,102
mean STS scores were 5.8% and 4.5%99,102 and a high percentage
were considered frail. Thus the results are valid only for comparable
patient groups. Overall, rates of vascular complications, pacemaker
implantation and paravalvular regurgitation were significantly higher for
TAVI, while the degree of excess depended on the device used.101,102
On the other hand, severe bleeding, acute kidney injury and new-onset
atrial fibrillation were significantly more frequent with surgery, whereas
no difference was observed in the rate of cerebrovascular
events.101,102 The favourable results of TAVI have been reproduced in
multiple large-scale, nationwide registries supporting the generalizabil-
ity of outcomes observed in randomized controlled trials. This favours
the use of TAVI over surgery in elderly patients at increased surgical
risk. However, the final decision between SAVR and TAVI (including
the choice of access route) should be made by the Heart Team after
careful individual evaluation. Table 7 provides aspects that should be
considered for the individual decision. Balloon valvuloplasty may be
considered as a bridge to surgery or TAVI, or diagnostically.
5.2.3 Asymptomatic aortic stenosis
Management of asymptomatic severe aortic stenosis remains contro-
versial. The available studies do not provide convincing data to
SAVR should be considered in patients with moderate aortic stenosise undergoing CABG or surgery of the ascending aorta or of another
valve after Heart Team decision.
IIa C
BNP = B-type natriuretic peptide; CABG, coronary artery bypass grafting; CT = computed tomography; EuroSCORE = European System for Cardiac Operative Risk
Evaluation; LV = left ventricular; LVEF = left ventricular ejection fraction; SAVR = surgical aortic valve replacement; STS = Society of Thoracic Surgeons; TAVI = transcatheter
aortic valve implantation; Vmax = peak transvalvular velocity.
aClass of recommendation.
bLevel of evidence.
cIn patients with a small valve area but low gradient despite preserved LVEF, explanations for this finding other than the presence of severe aortic stenosis are frequent and
must be carefully excluded. See Figure 2 and Table 6.
dSTS score (calculator: http://riskcalc.sts.org/stswebriskcalc/#/calculate); EuroSCORE II (calculator: http://www.euroscore.org/calc.html); logistic EuroSCORE I (calculator:
http://www.euroscore.org/calcge.html); scores have major limitations for practical use in this setting by insufficiently considering disease severity and not including major risk fac-
tors such as frailty, porcelain aorta, chest radiation, etc.103 EuroSCORE I markedly overestimates 30-day mortality and should therefore be replaced by the better-performing
EuroSCORE II with this regard; it is nevertheless provided here for comparison, as it has been used in many TAVI studies/registries and may still be useful to identify the sub-
groups of patients for decision between intervention modalities and to predict 1-year mortality.
eModerate aortic stenosis is defined as a valve area of 1.0–1.5 cm2 or a mean aortic gradient of 25–40 mmHg in the presence of normal flow conditions. However, clinical judge-
ment is required.
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.. support the general recommendation of early SAVR, even in patients
with asymptomatic very severe aortic stenosis.92,106 The decision to
operate on asymptomatic patients requires careful weighing of the
benefits against the risks. This section refers only to patients who are
candidates for SAVR, as TAVI is not recommended in asymptomatic
patients. Early elective surgery is indicated in asymptomatic patients
with depressed LV function not due to other causes and in patients
who develop symptoms during exercise testing.85,107
Predictors of symptom development and adverse outcomes in
asymptomatic patients include clinical characteristics (older age, pres-
ence of atherosclerotic risk factors), echocardiographic parameters
(valve calcification, peak aortic jet velocity,92,108 LVEF, rate of haemo-
dynamic progression,92 increase in mean gradient >20 mmHg with
exercise,86 excessive LV hypertrophy,109 abnormal longitudinal LV
function110 and pulmonary hypertension111) and biomarkers (ele-
vated plasma levels of natriuretic peptides, although the precise cut-
off values have not yet been well defined89,90). When early elective
surgery is considered in patients with normal exercise performance
because of the presence of such outcome predictors, the operative
risk should be low (see table of recommendations in section 5.2
Indications for interventions in aortic stenosis). In patients without
predictive factors, watchful waiting appears safe and early surgery is
unlikely to be beneficial.
5.3 Medical therapy
No medical therapy for aortic stenosis can improve outcome
compared with the natural history. Randomized trials have
consistently shown that statins do not affect the progression of
aortic stenosis.112 Patients with symptoms of heart failure who
are unsuitable candidates for surgery or TAVI or who are cur-
rently awaiting surgical or catheter intervention should be medi-
cally treated according to the heart failure guidelines.113
Coexisting hypertension should be treated. Medical treatment
should be carefully titrated to avoid hypotension and patients
should be re-evaluated frequently. Maintenance of sinus rhythm is
important.
5.4 Serial testing
In the asymptomatic patient, the wide variability in the rate of pro-
gression of aortic stenosis stresses the need for patients to be care-
fully educated about the importance of follow-up and reporting
symptoms as soon as they develop. Stress tests should determine the
recommended level of physical activity. Follow-up evaluation should
focus on haemodynamic progression, LV function and hypertrophy
and dimensions of the ascending aorta.
Asymptomatic severe aortic stenosis should be re-evaluated at
least every 6 months for the occurrence of symptoms (change in
exercise tolerance, ideally using exercise testing if symptoms
are doubtful) and change in echocardiographic parameters.
Measurement of natriuretic peptides should be considered.
In the presence of significant calcification, mild and moderate aortic
stenosis should be re-evaluated yearly. In younger patients with mild
aortic stenosis and no significant calcification, intervals may be
extended to 2–3 years.
Table 7 Aspects to be considered by the Heart Team
for the decision between SAVR and TAVI in patients at
increased surgical risk (see Table of Recommendations
in section 5.2.)
CABG = coronary artery bypass grafting; CAD = coronary artery disease;
EuroSCORE = European System for Cardiac Operative Risk Evaluation; LV = left
ventricle; SAVR = surgical aortic valve replacement; STS = Society of Thoracic
Surgeons; TAVI = transcatheter aortic valve implantation.
aSTS score (calculator: http://riskcalc.sts.org/stswebriskcalc/#/calculate); EuroSCORE
II (calculator: http://www.euroscore.org/calc.html); logistic EuroSCORE I (calculator:
http://www.euroscore.org/calcge.html); scores have major limitations for practical
use in this setting by insufficiently considering disease severity and not including
major risk factors such as frailty, porcelain aorta, chest radiation etc.103EuroSCORE I
markedly overestimates 30-day mortality and should therefore be replaced by the
better performing EuroSCORE II with this regard; it is nevertheless provided here
for comparison as it has been used in many TAVI studies/registries and may still be
useful to identify the subgroups of patients for decision between intervention modal-
ities and to predict 1-year mortality.
bSee section 3.3, general comments, for frailty assessment.
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5.5 Special patient populations
Combined SAVR and CABG carry a higher risk than isolated SAVR.
However, SAVR late after CABG is also associated with significantly
increased risk. Data from retrospective analyses indicate that patients
in whom CABG is indicated and who have moderate aortic stenosis
will in general benefit from concomitant SAVR. It has also been sug-
gested that if age is < 70 years and, more importantly, an average rate
of aortic stenosis progression of 5 mmHg/year is documented,
patients may benefit from valve replacement at the time of coronary
surgery once the baseline peak gradient exceeds 30 mmHg.114
Individual judgement is recommended, taking into consideration BSA,
haemodynamic data, leaflet calcification, aortic stenosis progression
rate, patient life expectancy and associated comorbidities, as well as
the individual risk of either concomitant valve replacement or late
reoperation.93 Patients with severe symptomatic aortic stenosis and
diffuse CAD that cannot be revascularized should not be denied
SAVR or TAVI.
Combined PCI and TAVI has been shown to be feasible but
requires more data before a firm recommendation can be made. The
chronology of interventions should be the subject of individualized
discussion based on the patient’s clinical condition, extent of CAD
and myocardium at risk.
When mitral regurgitation is associated with severe aortic stenosis,
its severity may be overestimated in the presence of the high ventric-
ular pressures and careful quantification is required. As long as there
are no morphological leaflet abnormalities (flail or prolapse, post-
rheumatic changes or signs of infective endocarditis), mitral annulus
dilatation or marked abnormalities of LV geometry, surgical interven-
tion on the mitral valve is in general not necessary. Non-severe sec-
ondary mitral regurgitation mostly improves after the aortic valve is
treated. In patients with severe mitral regurgitation, combined or
sequential TAVI and percutaneous mitral edge-to-edge repair have
been demonstrated to be feasible, but there is not enough experi-
ence to make recommendations.
Concomitant aneurysm/dilatation of the ascending aorta requires
the same treatment as in aortic regurgitation (see section 4).
For congenital aortic stenosis, see the ESC guidelines on grown-up
congenital heart disease.115
Key points
• The diagnosis of severe aortic stenosis requires consideration of
AVA together with flow rate, pressure gradients (the most
robust measurement), ventricular function, size and wall thick-
ness, degree of valve calcification and blood pressure, as well as
functional status.
• The assessment of the severity of aortic stenosis in patients with
low gradient and preserved ejection fraction remains particularly
challenging.
• The strongest indication for intervention remains symptoms of
aortic stenosis (spontaneous or on exercise testing).
• The presence of predictors of rapid symptom development can
justify early surgery in asymptomatic patients, particularly when
surgical risk is low.
• Although current data favour TAVI in elderly patients who are at
increased risk for surgery, particularly when a transfemoral access
is possible, the decision between TAVI and SAVR should be
made by the Heart Team after careful, comprehensive evaluation
of the patient, weighing individually the risks and benefits.
Gaps in evidence
• The impact of earlier markers of LV dysfunction on postopera-
tive outcome requires further research.
• The identification of patients with low-gradient aortic stenosis
who have severe stenosis and would benefit from intervention
requires improvement.
• The criteria for identification of patients who would benefit from
early elective surgery in asymptomatic severe aortic stenosis
requires further research.
• Long-term follow-up after TAVI is required; in particular, the
long-term durability of the valves needs to be studied.
• Criteria for the decision between TAVI and SAVR in patients at
increased operative risk who are eligible for both must be refined
and must be studied in surgical low-risk patients.
• Criteria for when TAVI should no longer be performed since it
would be futile need to be further defined.
6. Mitral regurgitation
Mitral regurgitation is the second-most frequent indication for valve
surgery in Europe.47 It is essential to distinguish primary from secon-
dary mitral regurgitation, particularly regarding surgical and transcath-
eter interventional management.116 The current background
information and detailed discussion of the data for the following sec-
tion of these Guidelines can be found in ESC CardioMed.
6.1 Primary mitral regurgitation
In primary mitral regurgitation, one or several components of the mitral
valve apparatus are directly affected. The most frequent aetiology is
degenerative (prolapse, flail leaflet). Endocarditis as one of the causes of
primary mitral regurgitation is discussed in specific ESC guidelines.28
6.1.1 Evaluation
Echocardiography is the principal investigation used to assess the
severity and mechanism of mitral regurgitation, its consequences for
the LV (function and remodelling), left atrium (LA) and pulmonary
circulation, as well as the likelihood of repair.
Quantification should be performed in an integrative way, including
qualitative, semi-quantitative and quantitative parameters. The criteria for
defining severe primary mitral regurgitation are summarized in Table 4.2,7
A precise anatomical description of the lesions, using the segmental
and functional anatomy according to the Carpentier classification,2,7
should be performed to assess the feasibility of repair. TTE also
assesses mitral annular dimensions and the presence of calcification.
TTE is diagnostic in most cases, but TOE is recommended, particu-
larly in the presence of suboptimal image quality.117 Three-
dimensional echocardiography provides additional information for
selecting the appropriate repair strategy.
The consequences of mitral regurgitation on ventricular function
are assessed by measuring LV size and ejection fraction. LA volume,
systolic pulmonary artery pressure, tricuspid regurgitation and annu-
lar size and RV function are important additional parameters.
Determination of functional capacity and symptoms assessed by
cardiopulmonary exercise testing may be useful in asymptomatic
patients. Exercise echocardiography is useful to quantify exercise-
induced changes in mitral regurgitation,118 in systolic pulmonary
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artery pressure and in LV function. It may be particularly helpful in
patients with symptoms and uncertainty about the severity of mitral
regurgitation based on measurements at rest. In asymptomatic
patients, the significant increase of pulmonary artery pressure with
exercise (>60 mmHg) has been reported to be of prognostic
value.119 The use of global longitudinal strain could be of potential
interest for the detection of subclinical LV dysfunction but is limited
by inconsistent algorithms used by different echocardiographic
systems.
Neurohormonal activation is observed in mitral regurgitation, with
a potential value of elevated BNP levels and a change in BNP as pre-
dictors of outcome (particularly of symptom onset). In particular,
low plasma BNP has a high negative predictive value and may be help-
ful in the follow-up of asymptomatic patients.120
Figure 4 Management of severe chronic primary mitral regurgitation. AF = atrial fibrillation; BSA = body surface area; CRT = cardiac resynchroni-
zation therapy; HF = heart failure; LA = left atrial; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; SPAP =
systolic pulmonary arterial pressure.
aWhen there is a high likelihood of durable valve repair at a low-risk, valve repair should be considered (IIa C) in patients with LVESD
>_40 mm and one of the following is present: flail leaflet or LA volume >_60 mL/m2 BSA at sinus rhythm.
bExtended HF management includes the following: CRT; ventricular assist devices; cardiac restraint devices; heart transplantation.
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As echocardiographic measures of pulmonary pressure may show
disagreement with invasive measures, the measurement should be
invasively confirmed by right-heart catheterization if this is the only
indication for surgery.
6.1.2 Indications for intervention
Urgent surgery is indicated in patients with acute severe mitral regur-
gitation. In the case of papillary muscle rupture as the underlying dis-
ease, valve replacement is in general required.
Indications for surgery in severe chronic primary mitral regurgita-
tion are shown in the following table of recommendations (indica-
tions for intervention in severe primary mitral regurgitation) and in
Figure 4. Surgery is obviously indicated in symptomatic patients with
severe primary mitral regurgitation.121 An LVEF <_60% or LVESD
>_45 mm,122 atrial fibrillation123 and a systolic pulmonary pressure
>_50 mmHg124 predict a worse postoperative outcome independent
of the symptomatic status and have therefore become triggers for
surgery in asymptomatic patients. In patients with flail leaflet, an
LVESD of 40–44 mm has been reported to predict a worse outcome
compared with LVESD <40 mm.125 Significant LA dilatation despite
sinus rhythm has also been found to be a predictor of outcome.124 In
the presence of these two latter triggers, surgery should only be con-
sidered in heart valve centres and if surgical risk is low. An increase in
systolic pulmonary artery pressure >60 mmHg on exercise echocar-
diography has also been proposed for risk stratification.119 However,
criteria that may indicate surgery have not been sufficiently well
defined to be included in the current recommendations.
Watchful waiting is a safe strategy in asymptomatic patients with
severe primary mitral regurgitation and none of the above indications
for surgery,126 and ideally patients are followed in the setting of a
heart valve centre.32
Despite the absence of a randomized comparison between the
results of valve replacement and repair, it is widely accepted that,
when feasible, valve repair is the preferred treatment. Achieving a
durable valve repair is essential. Degenerative mitral regurgitation
due to segmental valve prolapse can be repaired with a low risk of
mitral regurgitation recurrence and reoperation. The reparability of
rheumatic lesions, extensive valve prolapse and—even more so—
mitral regurgitation with leaflet calcification or extensive annular cal-
cification is more challenging. Patients with a predictably complex
repair should undergo surgery in experienced repair centres with
high repair rates, low operative mortality and a record of durable
results.127,128 When repair is not feasible, mitral valve replacement
with preservation of the subvalvular apparatus is favoured. Additional
tricuspid valve repair should be performed as indicated in section 8.2
(see table of recommendations on indications for tricuspid valve
surgery).
Transcatheter mitral valve interventions have been developed to
correct primary mitral regurgitation either through a transseptal or a
transapical approach. Among the transcatheter procedures, currently
only the edge-to-edge mitral repair is widely adopted.129 Experience
with transcatheter annuloplasty, transapical chordal implantation or
valve replacement is still limited and general recommendations can-
not yet be made. Transcatheter mitral valve treatment should be dis-
cussed by the Heart Team in symptomatic patients who are at high
surgical risk or are inoperable. Percutaneous edge-to-edge repair is
generally safe and can improve symptoms and provide reverse LV
remodelling. However, the rate of residual mitral regurgitation up to
5 years is higher than with surgical repair.130
Indications for intervention in severe primary mitral
regurgitation
Recommendations Classa Levelb
Mitral valve repair should be the preferred
technique when the results are expected to be
durable.
I C
Surgery is indicated in symptomatic patients
with LVEF >30%.121,131,132
I B
Surgery is indicated in asymptomatic patients
with LV dysfunction (LVESD >_45 mmc and/or
LVEF <_60%).122,131
I B
Surgery should be considered in asymptomatic
patients with preserved LV function (LVESD
<45 mm and LVEF >60%) and atrial fibrillation
secondary to mitral regurgitation or pulmonary
hypertensiond (systolic pulmonary pressure at
rest >50mmHg).123,124
IIa B
Surgery should be considered in asymptomatic
patients with preserved LVEF (>60%) and LVESD
40–44 mmc when a durable repair is likely, surgi-
cal risk is low, the repair is performed in a heart
valve centre and at least one of the following find-
ings is present:
• flail leaflet or
• presence of significant LA dilatation (vol-
ume index >_60 mL/m2 BSA) in sinus
rhythm.
IIa C
Mitral valve repair should be considered in
symptomatic patients with severe LV dysfunc-
tion (LVEF <30% and/or LVESD >55 mm)
refractory to medical therapy when the likeli-
hood of successful repair is high and comorbid-
ity low.
IIa C
Mitral valve replacement may be considered in
symptomatic patients with severe LV dysfunc-
tion (LVEF <30% and/or LVESD >55 mm)
refractory to medical therapy when the likeli-
hood of successful repair is low and comorbid-
ity low.
IIb C
Percutaneous edge-to-edge procedure may be
considered in patients with symptomatic
severe primary mitral regurgitation who fulfil
the echocardiographic criteria of eligibility and
are judged inoperable or at high surgical risk by
the Heart Team, avoiding futility.
IIb C
BSA = body surface area; LA = left atrial; LV = left ventricular; LVEF = left ven-
tricular ejection fraction; LVESD = left ventricular end-systolic diameter; SPAP =
systolic pulmonary artery pressure.
aClass of recommendation.
bLevel of evidence.
cCut-offs refer to average-size adults and may require adaptations in patients
with unusually small or large stature.
dIf an elevated SPAP is the only indication for surgery, the value should be con-
firmed by invasive measurement.
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6.1.3 Medical therapy
In acute mitral regurgitation, nitrates and diuretics are used to reduce
filling pressures. Sodium nitroprusside reduces afterload and regurgi-
tant fraction. Inotropic agents and an intra-aortic balloon pump are of
use in hypotension and haemodynamic instability.
In chronic mitral regurgitation with good ventricular function,
there is no evidence to support the prophylactic use of vasodilators,
including ACE inhibitors. However, ACE inhibitors should be consid-
ered when heart failure has developed in patients who are not suit-
able for surgery or when symptoms persist after surgery. Beta-
blockers and spironolactone (or eplerenone) should also be consid-
ered as appropriate.
6.1.4 Serial testing
Asymptomatic patients with severe mitral regurgitation and LVEF
>60% should be followed clinically and echocardiographically every
6 months, ideally in the setting of a heart valve centre. Closer follow-
up is indicated if no previous evaluation is available and when meas-
ured variables show significant dynamic changes or are close to the
thresholds. When guideline indications for surgery are reached, early
surgery—within 2 months—is associated with better outcomes.133
Asymptomatic patients with moderate mitral regurgitation and pre-
served LV function can be followed on a yearly basis and echocar-
diography should be performed every 1–2 years.
6.2 Secondary mitral regurgitation
In secondary mitral regurgitation (previously also referred to as ‘func-
tional mitral regurgitation’), the valve leaflets and chordae are struc-
turally normal and mitral regurgitation results from an imbalance
between closing and tethering forces on the valve secondary to alter-
ations in LV geometry.134 It is most commonly seen in dilated or
ischaemic cardiomyopathies. Annular dilatation in patients with
chronic atrial fibrillation and LA enlargement can also be an underly-
ing mechanism.
6.2.1 Evaluation
Echocardiography is essential to establish the diagnosis of secondary
mitral regurgitation. In secondary mitral regurgitation, lower thresh-
olds have been proposed to define severe mitral regurgitation com-
pared with primary mitral regurgitation [20 mm2 for effective
regurgitant orifice area (EROA) and 30 mL for regurgitant volume],
owing to their association with prognosis.135 However, it is unclear if
prognosis is independently affected by mitral regurgitation compared
with LV dysfunction. So far, no survival benefit has been confirmed
for reduction of secondary mitral regurgitation.
For isolated mitral valve treatment (surgery or percutaneous
edge-to-edge repair) in secondary mitral regurgitation, thresholds of
severity of mitral regurgitation for intervention still need to be vali-
dated in clinical trials. The severity of secondary mitral regurgitation
should be reassessed after optimized medical treatment. The severity
of tricuspid regurgitation and RV size and function should also be
evaluated.
Secondary mitral regurgitation is a dynamic condition; echocardio-
graphic quantification of mitral regurgitation during exercise may
provide prognostic information of dynamic characteristics.
Myocardial viability testing may be useful in patients with ischaemic
secondary mitral regurgitation who are candidates for
revascularization.
6.2.2 Indications for intervention
The presence of chronic secondary mitral regurgitation is associated
with impaired prognosis.135 However, in contrast to primary mitral
regurgitation, there is currently no evidence that a reduction of sec-
ondary mitral regurgitation improves survival. The limited data
regarding secondary mitral regurgitation result in a lower level of evi-
dence for treatment recommendations (see table of recommenda-
tions on indications for mitral valve intervention in chronic secondary
mitral regurgitation) and highlight the importance of decision making
by the Heart Team. Heart failure and electrophysiology specialists
should be involved.
In patients with CAD undergoing revascularization, the evaluation
and decision to treat (or not to treat) ischaemic mitral regurgitation
should be made before surgery, as general anaesthesia may signifi-
cantly reduce the severity of regurgitation. When mitral regurgitation
severity is assessed intraoperatively, the use of acute volume chal-
lenge and an increase in afterload may be helpful.
The optimal surgical approach remains controversial.136 While
mitral valve repair with an undersized complete ring to restore leaflet
coaptation and valve competence is the preferred technique, valve
replacement should be considered in patients with echocardio-
graphic risk factors for residual or recurrent mitral regurgitation.2
Indications for surgery in secondary mitral regurgitation are partic-
ularly restrictive when concomitant revascularization is not an
option, owing to significant operative mortality, high rates of recur-
rent mitral regurgitation and the absence of a proven survival
benefit.137,138
Percutaneous edge-to-edge repair for secondary mitral regurgita-
tion is a low-risk option, but its efficacy to reduce mitral regurgitation
remains inferior to surgery.139 It can improve symptoms, functional
capacity and quality of life and may induce reverse LV remodelling.140
Similar to surgery, a survival benefit compared with ‘optimal’ medical
therapy according to current guidelines113 has not yet been proven.
In patients with markedly reduced LV function (ejection fraction
<_30%) and no option for revascularization who remain symptomatic
despite optimal heart-failure treatment [including cardiac resynchro-
nization therapy (CRT) when indicated], the decision between pallia-
tive mitral regurgitation treatment—catheter-based or surgical,
ventricular assist devices, heart transplantation—and continued con-
servative therapy should be made by the Heart Team after careful
individual evaluation of the patient. Valve intervention is generally not
an option when the ejection fraction is < 15%.
There is continuing debate regarding the management of moder-
ate ischaemic mitral regurgitation in patients undergoing CABG. A
recent randomized controlled trial could not show a benefit of con-
comitant valve surgery.141 Surgery is more likely to be considered if
myocardial viability is present and if comorbidity is low. In patients
capable of exercising, exercise-induced dyspnoea and a large increase
in mitral regurgitation severity and systolic pulmonary artery pressure
favour combined surgery.
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6.2.3 Medical therapy
Optimal medical therapy in line with the guidelines for the
management of heart failure113 should be the first step in the man-
agement of all patients with secondary mitral regurgitation.
Indications for CRT should be evaluated in accordance with
related guidelines.113 If symptoms persist after optimization of
conventional heart failure therapy, options for mitral valve inter-
vention should be evaluated.
Key points
• Echocardiography is essential to assess the aetiology of mitral
regurgitation, as well as valve anatomy and function. An integra-
tive approach is needed to assess the severity of mitral
regurgitation.
• Indication for intervention in primary mitral regurgitation is
guided by symptoms and risk stratification that includes the
assessment of ventricular function and size, atrial fibrillation, sys-
tolic pulmonary pressure and LA size.
• In secondary mitral regurgitation, there is no conclusive evidence
for a survival benefit after mitral valve intervention. Mitral surgery
is recommended concomitantly in patients with an indication for
CABG and may be considered in patients who are symptomatic
despite optimal medical therapy (including CRT if indicated) or
who have a low surgical risk when revascularization is not
indicated.
• Mitral valve repair is the preferred method, but mitral valve
replacement should be considered in patients with unfavourable
morphological characteristics.
• Outcomes of mitral valve repair depend on surgeon experience
and centre-related volume.
• Percutaneous edge-to-edge repair may be considered in patients
at high surgical risk, avoiding futility.
Gaps in evidence
• The potential role of elective mitral valve surgery in asympto-
matic patients with severe primary mitral regurgitation with pre-
served ventricular size and function who are in sinus rhythm and
have not developed a high pulmonary artery pressure requires
investigation in a randomized controlled trial.
• The impact of earlier markers of LV dysfunction on postopera-
tive outcome requires further research.
• The thresholds to define severe secondary mitral regurgitation
are controversial and need to be evaluated with regards to their
impact on prognosis after mitral valve intervention.
• The potential impact of mitral valve intervention (surgery and
catheter intervention) on survival in patients with secondary
mitral regurgitation needs to be evaluated.
• The new percutaneous valve repair and valve implantation tech-
niques require further evaluation.
7. Mitral stenosis
The incidence of rheumatic mitral stenosis has greatly decreased in
industrialized countries.142 Degenerative calcific mitral valve disease
is now encountered mainly in elderly patients.143 Percutaneous mitral
commissurotomy (PMC) has had a significant impact on the manage-
ment of rheumatic mitral stenosis. The current background informa-
tion and detailed discussion of the data for the following section of
these Guidelines can be found in ESC CardioMed.
7.1 Evaluation
Echocardiography is the preferred method for diagnosing mitral
stenosis and for assessing its severity and haemodynamic consequen-
ces. However, several specific issues should be considered. Valve
area using planimetry is the reference measurement of mitral stenosis
severity, whereas mean transvalvular gradient and pulmonary
Indications for mitral valve intervention in chronic sec-
ondary mitral regurgitationa
Recommendations Classb Levelc
Surgery is indicated in patients with severe
secondary mitral regurgitation undergoing
CABG and LVEF >30%.
I C
Surgery should be considered in sympto-
matic patients with severe secondary mitral
regurgitation, LVEF <30% but with an
option for revascularization and evidence of
myocardial viability.
IIa C
When revascularization is not indicated,
surgery may be considered in patients with
severe secondary mitral regurgitation and
LVEF >30% who remain symptomatic
despite optimal medical management
(including CRT if indicated) and have a low
surgical risk.
IIb C
When revascularization is not indicated and
surgical risk is not low, a percutaneous
edge-to-edge procedure may be considered
in patients with severe secondary mitral
regurgitation and LVEF >30% who remain
symptomatic despite optimal medical man-
agement (including CRT if indicated) and
who have a suitable valve morphology by
echocardiography, avoiding futility.
IIb C
In patients with severe secondary mitral
regurgitation and LVEF <30% who remain
symptomatic despite optimal medical
management (including CRT if indicated)
and who have no option for revasculariza-
tion, the Heart Team may consider a percu-
taneous edge-to-edge procedure or valve
surgery after careful evaluation for a ventric-
ular assist device or heart transplant accord-
ing to individual patient characteristics.
IIb C
CABG = coronary artery bypass grafting; CRT = cardiac resynchronization ther-
apy; LVEF = left ventricular ejection fraction.
aSee section 6.2.1 for quantification of secondary mitral regurgitation, which must
always be performed under optimal treatment.
bClass of recommendation.
cLevel of evidence.
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Figure 5 Management of clinically significant mitral stenosis. CI = contra-indication; MS = mitral stenosis; PMC = percutaneous mitral
commissurotomy.
aHigh thromboembolic risk: history of systemic embolism, dense spontaneous contrast in the left atrium, new-onset atrial fibrillation.
High-risk of haemodynamic decompensation: systolic pulmonary pressure >50 mmHg at rest, need for major non-cardiac surgery, desire
for pregnancy. bSurgical commissurotomy may be considered by experienced surgical teams or in patients with contra-indications to PMC.
cSee table of recommendations on indications for PMC and mitral valve surgery in clinically significant mitral stenosis in section 7.2.
dSurgery if symptoms occur for a low level of exercise and operative risk is low.
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pressures reflect its consequences and have a prognostic value.3 TTE
usually provides sufficient information for routine management.
Scoring systems have been developed to help assess suitability for
PMC.144–146 TOE should be performed to exclude LA thrombus
before PMC or after an embolic episode. Echocardiography also plays
an important role in monitoring the results of PMC during the proce-
dure. Stress testing is indicated in patients with no symptoms or
symptoms equivocal or discordant with the severity of mitral steno-
sis. Exercise echocardiography may provide additional objective
information by assessing changes in mitral gradient and pulmonary
artery pressure.
7.2 Indications for intervention
The type of treatment, as well as its timing, should be decided on
the basis of clinical characteristics, valve anatomy and local exper-
tise. In general, indication for intervention should be limited to
patients with clinically significant (moderate to severe) mitral
stenosis (valve area <1.5 cm2). However, PMC may be considered
in symptomatic patients with a valve area >1.5 cm2 if symptoms
cannot be explained by another cause and if the anatomy is
favourable.
The management of clinically significant mitral stenosis is summar-
ized in Figure 5 and the indications and contraindications for PMC are
provided in the table of recommendations on indications for PMC
and mitral valve surgery in clinically significant mitral stenosis and in
Table 8. Intervention should be performed in symptomatic patients.
Most patients with favourable valve anatomy currently undergo
PMC, however, open commissurotomy may be preferred by experi-
enced surgeons in young patients with mild to moderate mitral
regurgitation.
In patients with unfavourable anatomy, decision making as to the
type of intervention is still a matter of debate and must take into
account the multifactorial nature of predicting the results of
PMC.147–149 PMC should be considered as an initial treatment for
selected patients with mild to moderate calcification or impaired sub-
valvular apparatus who have otherwise favourable clinical character-
istics. Surgery, which is mostly valve replacement, is indicated in the
other patients.
Owing to the small but definite risk inherent to PMC, truly
asymptomatic patients, as assessed using stress testing, are usually not
candidates for the procedure, except in cases where there is increased
risk of systemic embolism or haemodynamic decompensation. In such
patients, PMC should only be performed if they have favourable char-
acteristics and if it is undertaken by experienced operators.
In asymptomatic patients with mitral stenosis, surgery is limited to
those rare patients at high risk of cardiac complications who have
contraindications for PMC and are at low risk for surgery.
The most important contraindication to PMC is LA thrombus
(Table 8). However, when the thrombus is located in the LA append-
age, PMC may be considered in patients without urgent need for
intervention, provided repeat TOE shows the thrombus has disap-
peared after 1–3 months of oral anticoagulation. Surgery is indicated
if the thrombus persists.
7.3 Medical therapy
Diuretics, beta-blockers, digoxin or heart rate–regulating calcium
channel blockers can transiently improve symptoms. Anticoagulation
with a target international normalized ratio (INR) between 2 and 3 is
indicated in patients with either new-onset or paroxysmal atrial
fibrillation.
In patients in sinus rhythm, oral anticoagulation is indicated when
there has been a history of systemic embolism or a thrombus is
present in the LA (recommendation class I, level of evidence C) and
should also be considered when TOE shows dense spontaneous
echocardiographic contrast or an enlarged LA (M-mode diameter
>50 mm or LA volume >60 mL/m2) (recommendation class IIa, level
of evidence C). Patients with moderate to severe mitral stenosis and
Indications for PMC and mitral valve surgery in clinically
significant (moderate or severe) mitral stenosis (valve
area 1.5 cm2)
Recommendations Classa Levelb
PMC is indicated in symptomatic patients
without unfavourable characteristicsc for
PMC.144,146,148
I B
PMC is indicated in any symptomatic
patients with a contraindication or a high
risk for surgery.
I C
Mitral valve surgery is indicated in sympto-
matic patients who are not suitable for
PMC.
I C
PMC should be considered as initial treat-
ment in symptomatic patients with subopti-
mal anatomy but no unfavourable clinical
characteristics for PMC.c
IIa C
PMC should be considered in asymptomatic
patients without unfavourable clinical and
anatomical characteristicsc for PMC and:
• high thromboembolic risk (history of
systemic embolism, dense spontaneous
contrast in the LA, new-onset or parox-
ysmal atrial fibrillation), and/or
• high risk of haemodynamic decompensa-
tion (systolic pulmonary pressure
>50 mmHg at rest, need for major non-
cardiac surgery, desire for pregnancy).
IIa C
LA = left atrium; PMC = percutaneous mitral commissurotomy.
aClass of recommendation.
bLevel of evidence.
cUnfavourable characteristics for PMC can be defined by the presence of several
of the following characteristics. Clinical characteristics: old age, history of com-
missurotomy, New York Heart Association class IV, permanent atrial fibrillation,
severe pulmonary hypertension. Anatomical characteristics: echocardiographic
score >8, Cormier score 3 (calcification of mitral valve of any extent as assessed
by fluoroscopy), very small mitral valve area, severe tricuspid regurgitation. For
the definition of scores see Table 9.
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persistent atrial fibrillation should be kept on vitamin K antagonist
(VKA) treatment and not receive NOACs.
Cardioversion is not indicated before intervention in patients with
severe mitral stenosis, as it does not durably restore sinus rhythm. If
atrial fibrillation is of recent onset and the LA is only moderately
enlarged, cardioversion should be performed soon after successful
intervention.
7.4 Serial testing
Asymptomatic patients with clinically significant mitral stenosis who
have not undergone intervention should be followed up yearly by
means of clinical and echocardiographic examinations and at longer
intervals (2–3 years) in case of moderate stenosis.
Management of patients after successful PMC is similar to that of
asymptomatic patients. Follow-up should be more frequent if asymp-
tomatic restenosis occurs. When PMC is not successful, surgery
should be considered early unless there are definite
contraindications.
Table 9 Echo scores: Wilkins score,145 Cormier score,150 and Echo Score “Revisited” for immediate outcome
prediction146
Risk groups for Echo score “Revisited”: low (score 0 - 3); intermediate (score 4 - 5); high (score 6 - 11)
Table 8 Contra-indications for percutaneous mitral
commissurotomy (PMC)a
CAD = coronary artery disease.
aPMC may be considered in patients with valve area >1.5 cm
2
with symptoms
that cannot be explained by another cause and if the anatomy is favourable.
ESC/EACTS Guidelines 2765
Downloaded from https://academic.oup.com/eurheartj/article-abstract/38/36/2739/4095039
by University of Zurich user
on 03 April 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
7.5 Special patient populations
When restenosis with symptoms occurs after surgical commissurot-
omy or PMC, reintervention in most cases requires valve replace-
ment, but PMC can be proposed in selected candidates with
favourable characteristics if the predominant mechanism is commis-
sural refusion.151
In the elderly population with rheumatic mitral stenosis when sur-
gery is high risk, PMC is a useful option, even if only palliative. In other
elderly patients, surgery is preferable.146,148,149 However, in elderly
patients with degenerative mitral stenosis with severely calcified
mitral annulus, surgery is very high risk. As there is no commissural
fusion in these cases, degenerative mitral stenosis is not amenable to
PMC.143 If degenerative mitral stenosis is severe, very preliminary
experience has suggested that transcatheter valve implantation of a
TAVI bioprosthesis in the mitral position is feasible in symptomatic
elderly patients who are inoperable if the anatomy is suitable.152
In patients with severe mitral stenosis combined with severe aortic
valve disease, surgery is preferable when it is not contraindicated.
The management of patients in whom surgery is contraindicated is
difficult and requires a comprehensive and individualized evaluation
by the Heart Team.
In cases with severe mitral stenosis with moderate aortic valve dis-
ease, PMC can be performed to postpone the surgical treatment of
both valves.
In patients with severe tricuspid regurgitation, PMC may be consid-
ered in selected patients with sinus rhythm, moderate atrial enlarge-
ment and functional tricuspid regurgitation secondary to pulmonary
hypertension. In other cases, surgery on both valves is preferred.153
Valve replacement is the only option for the treatment of rare
cases of severe mitral stenosis of non-rheumatic origin where com-
missural fusion is absent.
Key points
• Most patients with severe mitral stenosis and favourable valve
anatomy currently undergo PMC.
• Decision making as to the type of intervention in patients with
unfavourable anatomy is still a matter of debate and must take into
account the multifactorial nature of predicting the results of PMC.
Gaps in evidence
• The scores predicting the results and complications of PMC, par-
ticularly those of severe mitral regurgitation, must be refined.
• The potential role of transcatheter mitral valve implantation in
high-risk patients is to be determined, particularly those with
severe degenerative mitral stenosis.
8. Tricuspid regurgitation
Pathological tricuspid regurgitation is more often secondary, due to
RV dysfunction following pressure and/or volume overload in the
presence of structurally normal leaflets.2 Possible causes of primary
tricuspid regurgitation are infective endocarditis (especially in intrave-
nous drug addicts),154 rheumatic heart disease, carcinoid syndrome,
myxomatous disease, endomyocardial fibrosis, Ebstein’s anomaly and
congenitally dysplastic valves, drug-induced valve diseases, thoracic
trauma and iatrogenic valve damage. The current background
information and detailed discussion of the data for the following sec-
tion of these Guidelines can be found in ESC CardioMed.
8.1. Evaluation
Echocardiography is the ideal technique to evaluate tricuspid regurgi-
tation. In primary tricuspid regurgitation, the aetiology can usually be
identified from specific abnormalities of the valve structure.28,115 In
secondary tricuspid regurgitation, the degree of dilatation of the
annulus, the RV dimension and function and the degree of tricuspid
valve deformation should be measured.2 Evaluation of tricuspid
regurgitation severity (integration of multiple qualitative and quantita-
tive parameters) and pulmonary systolic pressure should be carried
out as currently recommended (Table 4).2 It has to be noted that the
problem of elevated pulmonary vascular resistance may be disguised
in the presence of severe tricuspid regurgitation since its velocity may
be lower than expected in the case of pulmonary hypertension.
Evaluations of RV dimensions and function should be conducted
despite the existing limitations of current indices of RV function.53
The presence of associated lesions (looking carefully at the associated
valve lesions, particularly on the left side) and LV function should be
assessed.
In experienced laboratories, 3D measurements of RV volumes can
be considered, which may be similar to those obtained by CMR.155
However, when available, CMR is the preferred method for evaluat-
ing RV size and function and represents the gold standard for assess-
ing RV volumes and function.155
Cardiac catheterization is not needed to diagnose tricuspid regur-
gitation or estimate its severity but should be obtained in patients in
whom isolated tricuspid valve surgery is contemplated for secondary
tricuspid regurgitation to evaluate haemodynamics, in particular pul-
monary vascular resistance.
8.2. Indications for intervention
The timing of surgical intervention remains controversial, mostly due
to the limited data available and their heterogeneous nature (see
table of recommendations for indications for tricuspid valve surgery
and Figure 6).156–160 Surgery should be carried out sufficiently early to
avoid irreversible RV dysfunction.
In severe primary tricuspid regurgitation, surgery is not only rec-
ommended in symptomatic patients but should also be considered in
asymptomatic patients when progressive RV dilatation or decline of
RV function is observed. Although these patients respond well to diu-
retic therapy, delaying surgery is likely to result in irreversible RV
damage, organ failure and poor results of late surgical intervention.
In secondary tricuspid regurgitation, adding a tricuspid repair, if
indicated, during left-sided surgery does not increase operative risk
and has been demonstrated to provide reverse remodelling of the
RV and improvement of functional status even in the absence of sub-
stantial tricuspid regurgitation when annulus dilatation is
present.156,157,160 It should therefore be performed liberally.
Reoperation on the tricuspid valve in cases of persistent tricuspid
regurgitation after mitral valve surgery carries a high risk, mostly due
to the late referral and the consequently poor clinical condition of
patients. To improve the prognosis of patients in this challenging sce-
nario, the treatment of severe late tricuspid regurgitation following
left-sided valve surgery should be considered earlier, even in asymp-
tomatic patients, if there are signs of progressive RV dilatation or
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decline in RV function and in the absence of left-sided valve dysfunc-
tion, severe RV or LV dysfunction and severe pulmonary vascular dis-
ease/hypertension.
If possible, valve repair is preferable to valve replacement. Ring
annuloplasty, preferably with prosthetic rings, is key to surgery for
secondary tricuspid regurgitation.156,161 Valve replacement should be
considered when the tricuspid valve leaflets are significantly tethered
and the annulus is severely dilated. In the presence of transtricuspid
pacemaker leads, the technique used should be adapted to the
patient’s condition and the surgeon’s experience. Percutaneous
repair techniques are in their infancy and must be further evaluated
before any recommendations can be made.
Figure 6 Indications for surgery in tricuspid regurgitation. LV = left ventricular; RV = right ventricular; TA = tricuspid annulus; TR = tricuspid regur-
gitation; TV = tricuspid valve; TVR = tricuspid valve replacement.
aTA >_ 40 mm or > 21 mm/m2.
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.. 9. Tricuspid stenosis
Tricuspid stenosis is often combined with tricuspid regurgitation,
most frequently of rheumatic origin. It is therefore almost always
associated with left-sided valve lesions, particularly mitral stenosis,
that usually dominate the clinical presentation. Other causes are rare,
including congenital, drug-induced valve diseases, Whipple’s disease,
endocarditis and large right atrial tumour. The current background
information and detailed discussion of the data for the following sec-
tion of these Guidelines can be found in ESC CardioMed.
9.1 Evaluation
Echocardiography provides the most useful information. Tricuspid
stenosis is often overlooked and requires careful evaluation.
Echocardiographic evaluation of the anatomy of the valve and
its subvalvular apparatus is important to assess valve reparability. No
generally accepted grading of tricuspid stenosis severity exists, but a
mean gradient >_5 mmHg at normal heart rate is considered indicative
of clinically significant tricuspid stenosis.3 Catheterization is no longer
used for evaluating the severity of tricuspid stenosis.
9.2 Indications for intervention
The lack of pliable leaflet tissue is the main limitation for valve repair.
Even though this is still a matter of debate, biological prostheses for
valve replacement are usually preferred over mechanical ones because
of the high risk of thrombosis carried by the latter and the satisfactory
long-term durability of the former in the tricuspid position.162
Percutaneous balloon tricuspid dilatation has been performed in a
limited number of cases, either alone or alongside PMC, but fre-
quently induces significant regurgitation. There is a lack of data on
long-term results.163
Intervention on the tricuspid valve is usually carried out at the
time of intervention on the other valves in patients who are symp-
tomatic despite medical therapy. The choice between repair or
valve replacement depends on valve anatomy and surgical exper-
tise. Balloon commissurotomy can be considered in the rare cases
with anatomically suitable valves when tricuspid stenosis is iso-
lated, or additional mitral stenosis can also be treated interven-
tionally (see table of recommendations in section 7.2 listing
indications for PMC and mitral valve surgery in clinically significant
mitral stenosis).
9.3 Medical therapy
Diuretics are useful in the presence of heart failure but are of limited
long-term efficacy.
Key points
• Tricuspid stenosis is a rare condition, whereas tricuspid regurgita-
tion is more common, especially in its secondary form.
• For appropriate management, secondary tricuspid regurgitation
has to be clearly distinguished from primary tricuspid regurgitation.
Indications for tricuspid valve surgery
Recommendations Classa Levelb
Recommendations on tricuspid stenosis
Surgery is indicated in symptomatic patients
with severe tricuspid stenosis.c
I C
Surgery is indicated in patients with severe
tricuspid stenosis undergoing left-sided
valve intervention.d
I C
Recommendations on primary tricuspid regurgitation
Surgery is indicated in patients with severe
primary tricuspid regurgitation undergoing
left-sided valve surgery.
I C
Surgery is indicated in symptomatic patients
with severe isolated primary tricuspid regur-
gitation without severe RV dysfunction.
I C
Surgery should be considered in patients
with moderate primary tricuspid regurgita-
tion undergoing left-sided valve surgery.
IIa C
Surgery should be considered in asympto-
matic or mildly symptomatic patients with
severe isolated primary tricuspid regurgita-
tion and progressive RV dilatation or deteri-
oration of RV function.
IIa C
Recommendations on secondary tricuspid regurgitation
Surgery is indicated in patients with severe
secondary tricuspid regurgitation under-
going left-sided valve surgery.
I C
Surgery should be considered in patients
with mild or moderate secondary tricuspid
regurgitation with a dilated annulus
(>_40 mm or > 21 mm/m2 by 2D echocar-
diography) undergoing left-sided valve
surgery.
IIa C
Surgery may be considered in patients
undergoing left-sided valve surgery with
mild or moderate secondary tricuspid
regurgitation even in the absence of annular
dilatation when previous recent right-heart
failure has been documented.
IIb C
After previous left-sided surgery and in
absence of recurrent left-sided valve dysfunc-
tion, surgery should be considered in patients
with severe tricuspid regurgitation who are
symptomatic or have progressive RV dilata-
tion/dysfunction, in the absence of severe RV
or LV dysfunction and severe pulmonary vas-
cular disease/hypertension.
IIa C
2D = two-dimensional; LV = left ventricular; PMC = percutaneous mitral com-
missurotomy; RV = right ventricular.
aClass of recommendation.
bLevel of evidence.
cPercutaneous balloon valvuloplasty can be attempted as a first approach if tricus-
pid stenosis is isolated.
dPercutaneous balloon valvuloplasty can be attempted if PMC can be performed
on the mitral valve.
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..• Similar to mitral regurgitation, primary tricuspid regurgitation
requires intervention sufficiently early to avoid secondary damage
of the RV, which is associated with poor outcome.
• Secondary tricuspid regurgitation should be liberally treated at
the time of left-sided valve surgery.
• Consideration of isolated surgery of secondary tricuspid regurgi-
tation after previous left-sided valve surgery requires comprehen-
sive assessment of the underlying disease, pulmonary
haemodynamics and RV function.
Gaps in evidence
• Criteria for optimal timing of surgery in primary tricuspid regurgi-
tation require refinement.
• Criteria for concomitant tricuspid valve surgery at the time of
left-sided surgery in patients without severe tricuspid valve dis-
ease require refinement.
• The potential role of transcatheter tricuspid valve treatment in
high-risk patients needs to be determined.
10. Combined and multiple-valve
diseases
Significant stenosis and regurgitation can be found on the same
valve. Disease of multiple valves may be encountered in several
conditions, particularly in rheumatic and congenital heart disease,
but also less frequently in degenerative valve disease. There is a
lack of data on combined or multiple-valve diseases. This does not
allow for evidence-based recommendations.164 The current back-
ground information and detailed discussion of the data for the fol-
lowing section of these Guidelines can be found in ESC
CardioMed.
The general principles for the management of combined or multi-
ple-valve disease are as follows:
• When either stenosis or regurgitation is predominant, manage-
ment follows the recommendations concerning the predominant
VHD. When the severity of both stenosis and regurgitation is
balanced, indications for interventions should be based on symp-
toms and objective consequences rather than on the indices of
severity of stenosis or regurgitation. In this setting, consideration
of the pressure gradient that reflects the haemodynamic burden
of the valve lesion becomes more important than valve area and
measures of the regurgitation for the assessment of disease
severity.
• Besides the separate assessment of each valve lesion, it is
necessary to take into account the interaction between the
different valve lesions. As an illustration, associated mitral
regurgitation may lead to underestimation of the severity of
aortic stenosis, as decreased stroke volume due to mitral
regurgitation lowers the flow across the aortic valve and
hence the aortic gradient. This underlines the need to com-
bine different measurements, including assessment of valve
areas, if possible using methods that are less dependent on
loading conditions, such as planimetry.
• Indications for intervention are based on global assessment of
the consequences of the different valve lesions (i.e. symptoms or
presence of LV dilatation or dysfunction). Intervention can be
considered for non-severe multiple lesions associated with symp-
toms or leading to LV impairment.
• The decision to intervene on multiple valves should take into
account the extra surgical risk of combined procedures.
• The choice of surgical technique should take into account
the presence of the other VHD; repair remains the ideal
option.
The management of specific associations of VHD is detailed in the
individual sections of this document.
Key points
• In combined VHD, pathology is considered severe even if both
stenosis and regurgitation are only of moderate severity and
pressure gradients become of major importance for assessment.
• Management of multiple valve disease is dictated by the predomi-
nant VHD.
Gaps in evidence
• More data on the natural history and the impact of intervention
on outcome are required to better define the indications for
intervention.
11. Prosthetic valves
Every valve prosthesis introduces a new disease process. In practice,
the choice is between a mechanical and a biological prosthesis.
Randomized trials comparing both prostheses consistently
found similar survival, no significant difference in rates of valve
thrombosis and thromboembolism, higher rates of bleeding with
mechanical prostheses and higher rates of reintervention with bio-
prostheses.165–167 The current background information and detailed
discussion of the data for the following section of these Guidelines
can be found in ESC CardioMed.
11.1 Choice of prosthetic valve
The choice between a mechanical and a biological valve in adults is
determined mainly by estimating the risk of anticoagulation-related
bleeding and thromboembolism with a mechanical valve versus the
risk of structural valve deterioration with a bioprosthesis and by con-
sidering the patient’s lifestyle and preferences. Rather than setting
arbitrary age limits, prosthesis choice should be discussed in detail
with the informed patient, cardiologists and surgeons, taking into
account the factors detailed below (see tables of recommendations
in section 11.1). Bioprostheses should be considered in patients
whose life expectancy is lower than the presumed durability of the
bioprosthesis, particularly if comorbidities may necessitate further
surgical procedures, and in those with increased bleeding risk. In
women who wish to become pregnant, the high risk of thromboem-
bolic complications with a mechanical prosthesis during pregnancy
and the low risk of elective reoperation are incentives to consider a
bioprosthesis, despite the rapid occurrence of structural valve deteri-
oration in this age group.
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intervention
Thromboembolism and anticoagulant-related bleeding present the
majority of complications experienced by prosthetic valve recipients.
Endocarditis prophylaxis and management of prosthetic valve endo-
carditis are detailed in a separate ESC guideline.28
11.2.1 Baseline assessment and modalities of follow-up
All patients require lifelong follow-up by a cardiologist after valve sur-
gery to detect early deterioration in prosthetic function or ventricular
function or progressive disease of another heart valve. Clinical assess-
ment should be performed yearly or as soon as possible if new cardiac
symptoms occur. TTE should be performed if any new symptoms
Choice of the aortic/mitral prosthesis in favour of a mechanical prosthesis; the decision is based on the integration of
several of the following factors
Recommendations Classa Levelb
A mechanical prosthesis is recommended according to the desire of the informed patient and if there are no contraindi-
cations to long-term anticoagulation.c
I C
A mechanical prosthesis is recommended in patients at risk of accelerated structural valve deterioration.d I C
A mechanical prosthesis should be considered in patients already on anticoagulation because of a mechanical prosthesis
in another valve position.
IIa C
A mechanical prosthesis should be considered in patients <60 years of age for prostheses in the aortic position and
<65 years of age for prostheses in the mitral position.e
IIa C
A mechanical prosthesis should be considered in patients with a reasonable life expectancyf for whom future redo valve
surgery would be at high risk.
IIa C
A mechanical prosthesis may be considered in patients already on long-term anticoagulation due to the high risk for
thromboembolism.g
IIb C
LV = left ventricular.
aClass of recommendation.
bLevel of evidence.
cIncreased bleeding risk because of comorbidities, compliance concerns or geographic, lifestyle or occupational conditions.
dYoung age (<40 years), hyperparathyroidism.
eIn patients 60–65 years of age who should receive an aortic prosthesis and those between 65 and 70 years of age in the case of mitral prosthesis, both valves are acceptable
and the choice requires careful analysis of factors other than age.
fLife expectancy should be estimated at > 10 years according to age, sex, comorbidities and country-specific life expectancy.
gRisk factors for thromboembolism are atrial fibrillation, previous thromboembolism, hypercoagulable state and severe LV systolic dysfunction.
Choice of the aortic/mitral prosthesis in favour of a bioprosthesis; the decision is based on the integration of several of
the following factors
Recommendations Classa Levelb
A bioprosthesis is recommended according to the desire of the informed patient. I C
A bioprosthesis is recommended when good-quality anticoagulation is unlikely (compliance problems, not readily available) or contrain-
dicated because of high bleeding risk (previous major bleed, comorbidities, unwillingness, compliance problems, lifestyle, occupation).
I C
A bioprosthesis is recommended for reoperation for mechanical valve thrombosis despite good long-term anticoagulant control. I C
A bioprosthesis should be considered in patients for whom there is a low likelihood and/or a low operative risk of future redo valve
surgery.
IIa C
A bioprosthesis should be considered in young women contemplating pregnancy. IIa C
A bioprosthesis should be considered in patients >65 years of age for a prosthesis in the aortic position or > 70 years of age in a mitral
position or those with a life expectancyc lower than the presumed durability of the bioprosthesis.d
IIa C
aClass of recommendation.
bLevel of evidence.
cLife expectancy should be estimated according to age, sex, comorbidities and country-specific life expectancy.
dIn patients 60–65 years of age who should receive an aortic prosthesis and those between 65 and 70 years of age in the case of mitral prosthesis, both valves are acceptable
and the choice requires careful analysis of factors other than age.
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occur after valve replacement or if complications are suspected. After
transcatheter as well as surgical implantation of a bioprosthetic valve,
echocardiography, including the measurement of transprosthetic gra-
dients, should be performed within 30 days (preferably 30 days for
surgery) after valve implantation (i.e. baseline imaging), at 1 year after
implantation and annually thereafter.168 TOE should be considered if
TTE is of poor quality and in all cases of suspected prosthetic dysfunc-
tion or endocarditis.169,170 Cinefluoroscopy for mechanical valves and
MSCT scanning provide useful additional information if valve thrombus
or pannus are suspected to impair valve function.170
11.2.2 Antithrombotic management
11.2.2.1 General management
Antithrombotic management should address effective control of
modifiable risk factors for thromboembolism in addition to the pre-
scription of antithrombotic drugs.171 Indications for antithrombotic
therapy after valve repair or replacement are summarized in the table
of recommendations for indications for antithrombotic therapy after
valvular surgery.
In patients with surgical aortic bioprostheses, the use of low-dose
aspirin is now favoured as an alternative to postoperative anticoagu-
lant therapy, although this relies on low-level evidence.42,172,173
When postoperative anticoagulant therapy is indicated, oral anti-
coagulation should be started during the first postoperative days.
Intravenous unfractionated heparin (UFH), monitored to an activated
partial thromboplastin time of 1.5–2.0 times the control value, ena-
bles rapid anticoagulation to be obtained before the INR rises.42
Low-molecular-weight heparin (LMWH) seems to offer effective and
stable anticoagulation and has been used in observational series
mostly using enoxaparin.174,175 This is off-label use.
The first postoperative month is a high-risk period for throm-
boembolism. The addition of aspirin to anticoagulant therapy
decreases postoperative thromboembolic risk but increases bleeding
risk and cannot be recommended routinely.176
VKAs should be favoured when long-term anticoagulant therapy is
needed in patients with a bioprosthesis. Despite the absence of data
from clinical trials, NOACs can be used in patients who have atrial
fibrillation associated with a bioprosthesis after the third postopera-
tive month.43 There is no evidence to support the use of antiplatelet
agents beyond 3 months in patients with surgical bioprostheses who
do not have an indication other than the presence of the bioprosthe-
sis itself.
A combination of low-dose aspirin and a thienopyridine is com-
monly used early after TAVI, followed by aspirin or a thienopyridine
alone in patients who have no other indication for oral anticoagula-
tion. Recent data suggest that single antiplatelet therapy may have a
better safety profile than dual antiplatelet therapy after TAVI.177
Observational findings suggest that anticoagulant therapy reduces the
incidence of subclinical thrombosis compared with dual antiplatelet
therapy.178 The results of ongoing large-scale, dedicated trials are
needed to improve evidence in this field.
11.2.2.2 Target international normalized ratio
Target INR should be adapted to patient risk factors and the throm-
bogenicity of the prosthesis (Table 10).171 Recent randomized trials
supported lower target INRs for aortic prostheses.186–188 However,
limited statistical power, certain methodological concerns and the
restriction to certain prostheses and/or to the use of INR self-
management led the Task Force not to change recommendations for
target INR.
We recommend a median INR value rather than a range to avoid
considering extreme values in the target range as a valid target INR.
High variability of the INR is a strong independent predictor of
reduced survival after valve replacement. There is now evidence that
INR self-management reduces INR variability and clinical events,
including patients with heart valve prosthesis181; however, appropri-
ate training and regular quality control are required. However, moni-
toring by an anticoagulant clinic should be considered for patients
with unstable INR or anticoagulant-related complications. Systematic
genotyping of patients on VKA treatment is not recommended in the
absence of convincing clinical benefit and concerns regarding cost-
effectiveness.189
11.2.2.3 Management of vitamin K antagonist overdose and bleeding
The risk of major bleeding rises considerably when the INR exceeds
4.5 and increases exponentially above an INR of 6.0. An INR >_6.0
therefore requires rapid reversal of anticoagulation because of the
risk of subsequent bleeding.
In the absence of bleeding, management depends on the target
INR, the actual INR and the half-life of the VKA used. It is possible to
stop oral anticoagulation and to allow the INR to fall gradually or to
give oral vitamin K in increments of 1 or 2 mg.190 Immediate reversal
of anticoagulation using intravenous prothrombin complex concen-
trate and vitamin K is required only for severe bleeding, defined as
not amenable to local control, threatening life or important organ
function (e.g. intracranial bleeding), causing haemodynamic instability
or requiring an emergency surgical procedure or transfusion.190
There are no data suggesting that the risk of thromboembolism due
to transient reversal of anticoagulation outweighs the consequences
of severe bleeding in patients with mechanical prostheses. The opti-
mal time to restart anticoagulant therapy should be discussed in rela-
tion to the location of the bleeding event, its evolution and
interventions performed to stop bleeding and/or to treat an underly-
ing cause.191
Table 10 Target INR for mechanical prostheses
INR = international normalized ratio; LVEF = left ventricular ejection fraction.
aMitral or tricuspid valve replacement; previous thromboembolism; atrial fibrilla-
tion; mitral stenosis of any degree; LVEF <35%.
bCarbomedics, Medtronic Hall, ATS, Medtronic Open-Pivot, St Jude Medical, On-
X, Sorin Bicarbon.
cOther bileaflet valves with insufficient data.
dLillehei-Kaster, Omniscience, Starr-Edwards (ball-cage), Bjork-Shiley and other
tilting-disc valves.
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Indications for antithrombotic therapy in patients with a prosthetic heart valve or valve repair
Recommendations Classa Levelb
Mechanical prostheses
Oral anticoagulation using a VKA is recommended lifelong for all patients.179,180 I B
Bridging using therapeutic doses of UFH or LMWH is recommended when VKA treatment should be
interrupted.
I C
The addition of low-dose aspirin (75 - 100 mg/day) to VKA should be considered after thromboembolism
despite an adequate INR.
IIa C
The addition of low-dose aspirin (75 - 100 mg/day) to VKA may be considered in the case of concomitant
atherosclerotic disease.
IIb C
INR self-management is recommended provided appropriate training and quality control are performed.181 I B
In patients treated with coronary stent implantation, triple therapy with aspirin (75 - 100 mg/day), clopidogrel
(75 mg/day) and VKA should be considered for 1 month, irrespective of the type of stent used and the clinical
presentation (i.e. ACS or stable CAD).182
IIa B
Triple therapy comprising aspirin (75–100 mg/day), clopidogrel (75 mg/day) and VKA for >1 month and up to
6 months should be considered in patients with high ischaemic risk due to ACS or other anatomical/procedural
characteristics that outweighs the bleeding risk.182
IIa B
Dual therapy comprising VKA and clopidogrel (75 mg/day) should be considered as an alternative to 1-month
triple antithrombotic therapy in patients in whom the bleeding risk outweighs the ischaemic risk.183,184
IIa A
In patients who have undergone PCI, discontinuation of antiplatelet treatment should be
considered at 12 months.185
IIa B
In patients requiring aspirin and/or clopidogrel in addition to VKA, the dose intensity of VKA should be care-
fully regulated with a target INR in the lower part of the recommended target range and a time in the thera-
peutic range >65 - 70%.182,184
IIa B
The use of NOACs is contraindicated.45 III B
Bioprostheses
Oral anticoagulation is recommended lifelong for patients with surgical or transcatheter implanted biopros-
theses who have other indications for anticoagulation.c
I C
Oral anticoagulation using a VKA should be considered for the first 3 months after surgical implantation of a
mitral or tricuspid bioprosthesis.
IIa C
Oral anticoagulation using a VKA should be considered for the first 3 months after surgical mitral or tricuspid
valve repair.
IIa C
Low-dose aspirin (75 - 100 mg/day) should be considered for the first 3 months after surgical implantation of
an aortic bioprosthesis or valve-sparing aortic surgery.
IIa C
Dual antiplatelet therapy should be considered for the first 3–6 months after TAVI, followed by lifelong single
antiplatelet therapy in patients who do not need oral anticoagulation for other reasons.
IIa C
Single antiplatelet therapy may be considered after TAVI in the case of high bleeding risk. IIb C
Oral anticoagulation may be considered for the first 3 months after surgical implantation of an aortic
bioprosthesis.
IIb C
ACS = acute coronary syndrome; CAD = coronary artery disease; INR = international normalized ratio; LMWH = low-molecular-weight heparin; LV = left ventricular; PCI = percutane-
ous coronary intervention; NOAC = non-vitamin K antagonist oral anticoagulant; TAVI = transcatheter aortic valve implantation; UFH = unfractionated heparin; VKA = vitamin K
antagonist.
aClass of recommendation.
bLevel of evidence.
cAtrial fibrillation, venous thromboembolism, hypercoagulable state or, with a lesser degree of evidence, severely impaired LV dysfunction (ejection fraction <35%).
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.11.2.2.4 Combination of oral anticoagulants with antiplatelet drugs
The addition of aspirin with contemporary target INRs has not been
studied in patients without vascular disease.42 Underlying uncertain-
ties on the risk–benefit ratio of the combination of VKA with aspirin
account for discrepancies between different recommenda-
tions.192,193 When added to anticoagulation, antiplatelet agents
decrease thromboembolic risk but increase the risk of major bleed-
ing.194 Therefore they should not be prescribed to all patients with
prosthetic valves but should be reserved for specific indications
according to the analysis of benefit and increased risk of major
bleeding. If used, the lower recommended dose should be prescribed
(e.g. aspirin 75 - 100 mg/day).
Indications for the addition of an antiplatelet agent to oral
anticoagulants are detailed in section 11.2.2.1 (see table of recom-
mendations for indications for antithrombotic therapy in patients
with a prosthetic heart valve or valve repair) and in Figure 7.
The use of prasugrel or ticagrelor as part of triple therapy should
be avoided.37 During triple antithrombotic therapy, close moni-
toring of INR is advised and INR should be kept in the low target
range.
Figure 7 Antithrombotic therapy in patients with mechanical valve prosthesis undergoing PCI (adapted from the 2017 ESC Focused Update on
Dual Antiplatelet Therapy195). A = aspirin; ABC = age, biomarkers, clinical history; ACS = acute coronary syndrome; C = clopidogrel; mo. =
month(s); O = oral anticoagulation with a vitamin K antagonist; PCI = percutaneous coronary intervention. For more details regarding estimation of
bleeding risk (HAS-BLED and ABC score) see the 2017 ESC Focused Update on Dual Antiplatelet Therapy.195
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..11.2.2.5 Interruption of anticoagulant therapy for planned invasive
procedures
Anticoagulation during non-cardiac surgery requires careful manage-
ment based on risk assessment.196 It is recommended not to inter-
rupt oral anticoagulation for most minor surgical procedures
(including dental extraction, cataract removal) and those procedures
where bleeding is easily controlled.197 Major surgical procedures
require an INR <1.5. In patients with a mechanical prosthesis, oral
anticoagulant therapy should be stopped before surgery and bridging
using heparin is recommended.196 UFH remains the only approved
heparin treatment in patients with mechanical prostheses; intrave-
nous administration should be favoured over the subcutaneous
route. The use of subcutaneous LMWH, although off-label, is an
alternative to UFH for bridging. When LMWHs are used they should
be administered twice a day using therapeutic doses, adapted to
body weight and renal function and, if possible, with monitoring of
anti-Xa activity with a target of 0.5–1.0 U/mL. Fondaparinux should
not be used for bridging in patients with mechanical prosthesis.
Practical modalities of anticoagulation bridging are detailed in Figure 8.
If required, after a careful risk–benefit assessment, combined
aspirin therapy should be discontinued 1 week before a non-cardiac
procedure.
Oral anticoagulation can be continued at modified doses in the
majority of patients who undergo cardiac catheterization, in particu-
lar using the radial approach. In patients who require transseptal cath-
eterization for valvular interventions, direct LV puncture or
pericardial drainage, oral anticoagulants should be stopped and bridg-
ing anticoagulation administered.171
In patients who have a subtherapeutic INR during routine monitor-
ing, bridging with UFH or preferably LMWH in an outpatient setting
is indicated until a therapeutic INR value is reached.
11.2.3 Management of valve thrombosis
Obstructive valve thrombosis should be suspected promptly in any
patient with any type of prosthetic valve who presents with recent
dyspnoea or an embolic event. The diagnosis should be confirmed by
TTE and TOE, cinefluoroscopy or CT scan if promptly available.169,170
The management of mechanical prosthetic valve thrombosis is
high risk, whatever the option taken. Surgery is high risk because it is
most often performed under emergency conditions and is a reinter-
vention. On the other hand, fibrinolysis carries risks of bleeding, sys-
temic embolism and recurrent thrombosis that are higher than after
surgery.198
Emergency valve replacement is recommended for obstructive
prosthetic valve thrombosis in critically ill patients without a contrain-
dication to surgery (see table of recommendations in section 11.2.3
for management of prosthetic dysfunction and Figure 9).
Management of non-obstructive mechanical prosthetic valve
thrombosis depends mainly on the occurrence of a thromboembolic
event and the size of the thrombus (Figure 10). Surgery should be
considered for a large (>10 mm) non-obstructive prosthetic valve
thrombus complicated by embolism or which persists despite opti-
mal anticoagulation.199 Fibrinolysis may be considered if surgery is at
high risk but carries a risk of bleeding and thromboembolism.
Valve thrombosis occurs mainly in mechanical prostheses.
However, cases of thrombosis of bioprostheses have been reported
after surgery or transcatheter valve implantation.200,201 Subclinical
thrombosis of bioprostheses may be more frequent when assessed
by cardiac CT,202 and subclinical thrombosis of TAVI prostheses can
be associated with a moderate increase in transprosthetic gradients,
but the clinical consequences are unknown.203
Anticoagulation using a VKA and/or UFH is the first-line treatment
of bioprosthetic valve thrombosis.
Management of prosthetic valve dysfunction
Recommendations Classa Levelb
Mechanical prosthetic thrombosis
Urgent or emergency valve replacement is recom-
mended for obstructive thrombosis in critically ill
patients without serious comorbidity.
I C
Fibrinolysis (using recombinant tissue plasminogen
activator 10 mg bolus þ 90 mg in 90 min with UFH or
streptokinase 1 500 000 U in 60 min without UFH)
should be considered when surgery is not available or
is very high risk or for thrombosis of right-sided
prostheses.
IIa C
Surgery should be considered for large (>10 mm)
non-obstructive prosthetic thrombus complicated by
embolism.
IIa C
Bioprosthetic thrombosis
Anticoagulation using a VKA and/or UFH is recom-
mended in bioprosthetic valve thrombosis before con-
sidering reintervention.
I C
Haemolysis and paravalvular leak
Reoperation is recommended if paravalvular leak is
related to endocarditis or causes haemolysis requiring
repeated blood transfusions or leading to severe
symptoms.
I C
Transcatheter closure may be considered for para-
valvular leaks with clinically significant regurgitation in
surgical high-risk patients (Heart Team decision).
IIb C
Bioprosthetic failure
Reoperation is recommended in symptomatic patients
with a significant increase in transprosthetic gradient
(after exclusion of valve thrombosis) or severe
regurgitation.
I C
Reoperation should be considered in asymptomatic
patients with significant prosthetic dysfunction if reop-
eration is at low risk.
IIa C
Transcatheter valve-in-valve implantation in the aortic
position should be considered by the Heart Team
depending on the risk of reoperation and the type and
size of prosthesis.
IIa C
UFH = unfractionated heparin; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
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Figure 8 Main bridging steps for an intervention requiring interruption of oral anticoagulation in a patient with a mechanical prosthesis. Timing
should be individualized according to patient characteristics, actual INR, and the type of intervention (reproduced with permission from Iung and
Rodes-Cabau42). INR = international normalized ratio; IV = intravenous; LMWH = low-molecular-weight heparin; UFH = unfractionated heparin;
VKA = vitamin K antagonist.
aIV UFH may be favoured in patients at high thrombotic risk.
Figure 9 Management of left-sided obstructive mechanical prosthetic thrombosis. IV = intravenous; TOE = transoesophageal echocardiography;
TTE = transthoracic echocardiography; UFH = unfractionated heparin.
aRisk and benefits of both treatments should be individualized. The presence of a first-generation prosthesis is an incentive to surgery.
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Figure 10 Management of left-sided non-obstructive mechanical prosthetic thrombosis. TE = thromboembolism; TOE = transoesophageal echo-
cardiography; TTE = transthoracic echocardiography.
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11.2.4 Management of thromboembolism
Thromboembolism after valve surgery is multifactorial in origin.171
Thorough investigation of each episode of thromboembolism
is therefore essential (including cardiac and non-cardiac imaging)
(Figure 10) rather than simply increasing the target INR or adding an
antiplatelet agent. Prevention of further thromboembolic events
involves the treatment of risk factors, optimization of anticoagulation
control and the addition of low-dose aspirin (<_100 mg daily) after
careful analysis of the risk–benefit ratio.
11.2.5 Management of haemolysis and paravalvular leak
Blood tests for haemolysis should be part of routine follow-up after
valve replacement. Lactate dehydrogenase, although non-specific, is
related to the severity of haemolysis. The diagnosis of haemolytic
anaemia requires TOE to detect a paravalvular leak if TTE is not con-
tributory. Reoperation is recommended if the paravalvular leak is
related to endocarditis or causes haemolysis requiring repeated
blood transfusions or leading to severe symptoms (see table of rec-
ommendations in section 11.2.3 for management of prosthetic dys-
function). Medical therapy, including iron supplementation, beta-
blockers and erythropoietin, is indicated in patients with severe hae-
molytic anaemia when contraindications to surgery are present.
Transcatheter closure of a paravalvular leak is feasible, but experi-
ence is limited and there is presently no conclusive evidence to show
a consistent efficiency.204
11.2.6 Management of bioprosthetic valve failure
After transcatheter as well as surgical implantation of a bioprosthetic
valve, echocardiography including the measurement of transpros-
thetic gradients should be performed within 30 days (preferably30
days for surgery) after valve implantation (i.e. baseline imaging), at
1 year after implantation and annually thereafter.168 The definitions of
structural valve deterioration and bioprosthetic valve failure have
recently been standardized in a consensus publication.168
Indications for reintervention are detailed in the table of recom-
mendations for management of prosthetic dysfunction (section
11.2.3.).
Percutaneous balloon interventions should be avoided in the treat-
ment of stenotic left-sided bioprostheses.
Transcatheter valve-in-valve implantation is now an option
for treating degenerated bioprostheses in patients with increased
surgical risk. Experience is mostly for bioprostheses in the aortic
position and remains limited in the mitral position and even more
so in the tricuspid position.205,206 Valve-in-valve and valve-in-ring
procedures may be reasonable alternatives if the patient is at
increased surgical risk, but it is necessary that the multidisciplinary
Heart Team discusses every patient and chooses the best individual-
ized approach.
11.2.7 Heart failure
Heart failure after valve surgery should lead to a search for
prosthetic dysfunction or prosthesis-patient mismatch, deteriora-
tion of repair, LV dysfunction or progression of another valve
disease. Non-valvular-related causes such as CAD, hypertension
or sustained arrhythmias should also be considered. The manage-
ment of patients with heart failure should follow the relevant
guidelines.113
Key points
• The choice between a mechanical prosthesis and a bioprosthesis
should not overstress the role of age and should take into
account the wishes of the informed patient.
• Patients with a mechanical prosthesis require lifelong treatment
using VKA with a target INR adapted to the prosthesis and
patient characteristics.
• Low-dose aspirin should be added to VKA only in selected
patients with a mechanical prosthesis who have atherosclerosis
or recurrent embolism.
• The risk of thromboembolism and bleeding is higher during the
postoperative period and requires increased awareness of the
monitoring of anticoagulant therapy.
• The management of anticoagulant therapy during non-cardiac
surgery should be adapted to the type of surgery. Minor surgical
procedures generally do not require interruption of
anticoagulation.
Gaps of evidence
• The safety and efficacy of very-low-target INRs (median <2.5) in
patients with a mechanical prosthesis in the aortic position
should be further studied.
• The safety and efficacy of NOACs in patients with a mechanical
prosthesis require further research.
• The safety and efficacy of low-dose aspirin associated with con-
temporary target INRs in patients with a mechanical prosthesis,
according to the presence or absence of atherosclerosis, require
further evaluation.
• Optimal early antithrombotic therapy after implantation of surgi-
cal and transcatheter aortic bioprostheses needs to be better
defined.
• Long-term outcome data of transcatheter valve-in-valve and
valve-in-ring procedures are required.
12. Management during non-
cardiac surgery
Cardiovascular morbidity and mortality are increased in
patients with VHD who undergo non-cardiac surgery.
Symptomatic severe aortic stenosis or mitral stenosis may
require valve replacement or percutaneous intervention before
non-cardiac surgery. A detailed description of these recommen-
dations is available.196 The current background information and
detailed discussion of the data for the following section of these
Guidelines can be found in ESC CardioMed.
12.1 Preoperative evaluation
Echocardiography should be performed in any patient with VHD.
Determination of functional capacity is a pivotal step in preoperative
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..risk assessment, measured either by exercise test or ability to per-
form activities in daily life. The decision for management should be
taken after multidisciplinary discussion involving cardiologists, sur-
geons and anaesthesiologists.
12.2 Specific valve lesions
12.2.1 Aortic stenosis
In patients with severe aortic stenosis, urgent non-cardiac
surgery should be performed under careful haemodynamic
monitoring.
The management related to elective non-cardiac surgery
depends on the presence of symptoms and the type of sur-
gery.196,207,208 In symptomatic patients, aortic valve replacement
should be considered before non-cardiac surgery. In patients at
increased surgical risk, TAVI is a therapeutic option. In asympto-
matic patients, elective non-cardiac surgery can be performed
safely, albeit with a risk of worsening heart failure.207,208 If non-
cardiac surgery implies large volume shifts, aortic valve replace-
ment should be considered first (Figure 11).
12.2.2 Mitral stenosis
Non-cardiac surgery can be performed safely in patients with non-
significant mitral stenosis (valve area >1.5 cm2) and in asymptomatic
patients with significant mitral stenosis and a systolic pulmonary
artery pressure <50 mmHg.
In symptomatic patients or in patients with systolic pulmonary
artery pressure >50 mmHg, correction of mitral stenosis, by means
of PMC whenever possible, should be attempted before non-cardiac
surgery if it is high risk.
12.2.3 Aortic and mitral regurgitation
Non-cardiac surgery can be performed safely in asymptomatic
patients with severe mitral regurgitation or aortic regurgitation and
preserved LV function. The presence of symptoms or LV dysfunction
should lead to consideration of valvular surgery, but this is seldom
needed before non-cardiac surgery. If LV dysfunction is severe (ejec-
tion fraction <30%), non-cardiac surgery should be performed only if
strictly necessary, after optimization of medical therapy for heart
failure.
Figure 11 Management of severe aortic stenosis and elective non-cardiac surgery according to patient characteristics and type of surgery. AS =
aortic stenosis; AVR = aortic valve replacement; BAV = balloon aortic valvuloplasty; TAVI = transcatheter aortic valve implantation.
aClassification into three groups according to the risk of cardiac complications (30-day death and myocardial infarction) for non-cardiac
surgery (high-risk >5%; intermediate risk 1–5%; low risk <1%).196
bNon-cardiac surgery performed only if strictly needed. The choice between percutaneous aortic valvuloplasty and TAVI should take
into account patient life expectancy.
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12.3 Perioperative monitoring
Heart rate control (particularly in mitral stenosis) and careful fluid
management (particularly in aortic stenosis) are needed. TOE moni-
toring may be considered.
Key points
• In symptomatic patients with severe aortic stenosis, aortic valve
replacement or TAVI should be considered before non-cardiac
surgery.
• In patients with severe mitral stenosis and symptoms or pulmo-
nary artery pressure >50 mmHg, PMC should be attempted
before non-cardiac surgery.
13. Management during
pregnancy
Detailed guidelines on the management of cardiovascular disease
during pregnancy are available in another document.209
The decision for management during pregnancy should be taken
after multidisciplinary discussion involving cardiologists, obstetricians
and anaesthesiologists.209 Valve disease should be evaluated before
pregnancy and treated if necessary. Pregnancy should be discouraged
in severe mitral stenosis, severe symptomatic aortic stenosis
and with an aortic diameter >45 mm in Marfan syndrome or
> 27.5 mm/m2 in Turner syndrome.
Caesarean section is recommended for patients with severe mitral
or aortic stenosis, ascending aortic diameter >45 mm or severe pul-
monary hypertension, as well as women on oral anticoagulants in
preterm labour. The current background information and detailed
discussion of the data for the following section of these Guidelines
can be found in ESC CardioMed.
13.1 Native valve disease
Moderate or severe mitral stenosis with a valve area <1.5 cm2 in
pregnant women is usually poorly tolerated. PMC should be consid-
ered in severely symptomatic patients (NYHA class III-IV) and/or
those with systolic pulmonary artery pressure >50 mmHg despite
optimal therapy. PMC should be performed after the 20th week of
pregnancy in experienced centres.209
Complications of severe aortic stenosis occur mainly in patients
who were symptomatic before pregnancy and among those with
impaired LV function. Evaluation with an exercise test is recom-
mended before pregnancy.
Chronic mitral regurgitation and aortic regurgitation are well
tolerated, even when severe, provided LV systolic function is
preserved.
Surgery under cardiopulmonary bypass is associated with a foetal
mortality rate of 15–30%210 and should be restricted to the rare con-
ditions that threaten the mother’s life.
13.2 Prosthetic valves
Maternal mortality is estimated at 1–4% and serious events occur in
up to 40% of women with mechanical valves.211
Therapeutic anticoagulation is extremely important to avoid com-
plications. In patients requiring <_5 mg warfarin, oral anticoagulants
throughout pregnancy and a change to UFH before delivery is fav-
oured. In patients requiring higher doses, switching to LMWH during
the first trimester with strict anti-Xa monitoring (therapeutic range
0.8–1.2 IU/mL) and the use of oral anticoagulants afterwards is
favoured.209
Key points
• Pregnancy should be discouraged in women with severe mitral
stenosis and severe symptomatic aortic stenosis.
• Pregnancy in women with a mechanical valve, especially in the
mitral position, is associated with a high risk for maternal and foe-
tal complications. Therapeutic anticoagulation during pregnancy is
of utmost importance in these patients.
Gaps in evidence
The optimal management of pregnant women with mechanical heart
valves with regards to the antithrombotic regimen needs to be better
defined.
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14. To do and not to do messages from the Guidelines
Recommendaons Classa Levelb
Management of CAD in paents with VHD (adapted from Windecker et al.16)
Coronary angiographyc is recommended before valve surgery in paents with severe VHD and any of the 
following:
• history of cardiovascular disease
• suspected myocardial ischaemiad
• LV systolic dysfuncon
• in men aged over 40 years and postmenopausal women
• one or more cardiovascular risk factors.
I C
Coronary angiography is recommended in the evaluaon of moderate to severe secondary mitral 
regurgitaon.
I C
CABG is recommended in paents with a primary indicaon for aorc/mitral valve surgery and coronary artery 
diameter stenosis ≥70%.
I C
Management of atrial ﬁbrillaon in paents with VHD
The use of NOACs is not recommended in paents with atrial ﬁbrillaon and moderate to severe mitral 
stenosis.
III C
NOACS are contraindicated in paents with a mechanical valve. III B
I B
Surgery is indicated in asymptomac paents with resng LVEF ≤50%.57,58 I B
Surgery is indicated in paents undergoing CABG or surgery of the ascending aorta, or of another valve. I C
Heart Team discussion is recommended in selected paentsc in whom aorc valve repair may be a feasible 
alternave to valve replacement.
I C
Aorc valve repair, using the reimplantaon or remodelling with aorc annuloplasty technique, is 
recommended in young paents with aorc root dilaon and tricuspid aorc valves, when performed by 
experienced surgeons. 
I C
Surgery is indicated in paents with Marfan syndrome, who have aorc root disease with a maximal ascending 
aorc diameter ≥50 mm. 
I C
Indicaons for intervenon in aorc stenosis and recommendaons for the choice of intervenon mode
(B) Aorc root disease (irrespecve of the severity of aorc regurgitaon)
Intervenon is indicated in symptomac paents with severe, high-gradient aorc stenosis (mean gradient 
≥40 mmHg or peak velocity ≥4.0 m/s).91-93
I B
Intervenon is indicated in symptomac paents with severe low-ﬂow, low-gradient (<40 mmHg) aorc 
stenosis with reduced ejecon fracon, and evidence of ﬂow (contracle) reserve excluding pseudosevere 
aorc stenosis.
I C
Intervenon should not be performed in paents with severe comorbidies when the intervenon is unlikely 
to improve quality of life or survival.
III C
Aorc valve intervenons should only be performed in centres with both departments of cardiology and 
cardiac surgery on-site, and with structured collaboraon between the two, including a Heart Team (heart 
valve centres).
I C
The choice for intervenon must be based on careful individual evaluaon of technical suitability and 
weighing of risks and beneﬁts of each modality (aspects to be considered are listed in Table 7). In addition, 
the local expertise and outcomes data for the given intervention must be taken into account.
I C
SAVR is recommended in paents at low surgical risk (STS or EuroSCORE II <4% or logisc EuroSCORE I <10%
and no other risk factors not included in these scores, such as frailty, porcelain aorta, sequelae of 
chest radiation).93
I B
TAVI is recommended in paents who are not suitable for SAVR as assessed by the Heart Team.91,94 I B
In paents who are at increased surgical risk (STS or EuroSCORE II ≥4% or logisc EuroSCORE I ≥10%, or other 
risk factors not included in these scores such as frailty, porcelain aorta, sequelae of chest radiation), 
the decision between SAVR and TAVI should be made by the Heart Team according to the individual 
patient characteristics (see Table 7), with TAVI being favoured in elderly patients suitable for 
transfemoral access. 91,94-102
I B
SAVR is indicated in asymptomac paents with severe aorc stenosis and systolic LV dysfuncon (LVEF <50%) 
not due to another cause.
I C
SAVR is indicated in asymptomac paents with severe aorc stenosis and abnormal exercise test showing 
symptoms on exercise clearly related to aorc stenosis.
I C
(A) Severe aorc regurgitaon
Indicaons for surgery
Surgery is indicated in symptomac paents.57,58,66,67
SAVR is indicated in paents with severe aorc stenosis undergoing CABG, or surgery of the ascending aorta 
or of another valve. 
I C
45
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Indicaons for intervenon in severe primary mitral regurgitaon 
Mitral valve repair should be the preferred technique when the results are expected to be durable. I C
Surgery is indicated in symptomac paents with LVEF >30%.121,131,132 I B
Surgery is indicated in asymptomac paents with LV dysfuncon (LVESD ≥45 mm and/or LVEF 
≤60%).122,131 I B
Indicaons for mitral valve intervenon in chronic secondary mitral regurgitaon
Surgery is indicated in paents with severe secondary mitral regurgitaon undergoing CABG and LVEF >30%. I C
Indicaons for PMC and mitral valve surgery in clinically signiﬁcant (moderate or severe) mitral stenosis 
(valve area ≤1.5 cm²)
PMC is indicated in symptomac paents without unfavourable characteriscs for PMC.144,146,148 I B
PMC is indicated in any symptomac paents with a contraindicaon or a high risk for surgery. I C
Mitral valve surgery is indicated in symptomac paents who are not suitable for PMC. I C
Indicaons for tricuspid valve surgery 
Surgery is indicated in symptomac paents with severe tricuspid stenosis. I C
Surgery is indicated in paents with severe tricuspid stenosis undergoing le-sided valve intervenon. I C
Surgery is indicated in paents with severe primary tricuspid regurgitaon undergoing le-sided valve surgery. I C
Surgery is indicated in symptomac paents with severe isolated primary tricuspid regurgitaon without 
severe right-ventricular dysfuncon.
I C
Surgery is indicated in paents with severe secondary tricuspid regurgitaon undergoing le-sided valve 
surgery.
I C
Choice of the aorc/mitral prosthesis – in favour of a mechanical prosthesis; the decision is based on the 
integraon of several of the following factors
A mechanical prosthesis is recommended according to the desire of the informed paent and if there are no 
contraindicaons to long-term ancoagulaon.
I C
A mechanical prosthesis is recommended in paents at risk of accelerated structural valve deterioraon. I C
Choice of the aorc/mitral prosthesis – in favour of a bioprosthesis; the decision is based on the integraon 
of several of the following factors
A bioprosthesis is recommended according to the desire of the informed paent. I C
A bioprosthesis is recommended when good-quality ancoagulaon is unlikely (compliance problems, not 
readily available) or contraindicated because of high bleeding risk (previous major bleed, comorbidies, 
unwillingness, compliance problems, lifestyle, occupaon).
I C
A bioprosthesis is recommended for reoperaon for mechanical valve thrombosis despite good long-term 
ancoagulant control.
I C
Indicaons for anthromboc therapy in paents with mechanical prostheses and bioprostheses
Oral ancoagulaon using a VKA is recommended lifelong for all paents.179,180 I B
Mechanical prostheses
Bridging using therapeuc doses of UFH or LMWH is recommended when VKA treatment should be 
interrupted.
I C
INR self-management is recommended provided appropriate training and quality control are performed.181 I B
The use of NOACs is contraindicated.45 III B
Oral ancoagulaon is recommended lifelong for paents with surgical or transcatheter implanted 
bioprostheses who have other indicaons for ancoagulaon.
I C
Management of prosthec valve dysfuncon 
Bioprostheses
Urgent or emergency valve replacement is recommended for obstrucve thrombosis in crically ill paents 
without serious comorbidity.
I C
Ancoagulaon using a VKA and/or UFH is recommended in bioprosthec valve thrombosis before 
considering reintervenon.
I C
Reoperaon is recommended if paravalvular leak is related to endocardis or causes haemolysis requiring 
repeated blood transfusions or leading to severe symptoms.
I C
Reoperaon is recommended in symptomac paents with a signiﬁcant increase in transprosthec gradient 
(aer exclusion of valve thrombosis) or severe regurgitaon.
I C
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Vladimir Uspenskiy; San Marino: San Marino Society of Cardiology,
Marina Foscoli; Serbia: Cardiology Society of Serbia, Ljiljana Jovovic;
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